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Lipids are small molecules with large structural and chemical diversity. Over the 
past two decades, technologies such as chromatography and mass spectrometry 
have driven the biochemical analyses of complex lipid mixtures, tremendously 
advancing our knowledge of lipid diversity. Lipid extraction (preceding analysis), 
however, is still largely based on partitioning procedures developed in the 1950s. 
Although appropriate for many abundant components, these approaches result in 
variable recovery of the less-abundant and highly charged lipids, including 
phosphorylated signaling lipids. 
 Phosphate is common amongst biological lipids and present in either 
monoester and/or diester configurations, with most biologically active lipids 
containing at least one phospho-monoester, for example sphingosine-1-phosphate 
(S1P). Long-chain amino alcohols, generally referred to as long-chain bases 
(LCB), and their phosphorylated forms (LCB-P) display particularly diverse 
chemistries across biological species and tissues. In human plasma, the 
phosphorylated derivative of the LCB with a linear 18 carbon chain, 1,3-
dihydroxy, and C4 double bond, i.e. d18:1 S1P [(2S, 3R, 4E)-2-aminooctadec-4-
ene-1,3-diol], is the most abundant LCB-P. However, little is known about the 
existence of other LCB-Ps of different chemical and structural composition, 
despite the presence of various non-phosphorylated LCB precursors. Here, we 
sought to experimentally explore this potentially uncharacterized landscape using 
a capture/targeting approach (‗deep profiling‘) by specifically targeting phospho-
monoester lipids using imidazolium polymer and improve the detection of LCB-
XI 
 
Ps. With this improved method we discovered and characterized novel LCB-Ps in 
tissues from human and mouse, cell lines, D. melanogaster and S.cerevisiae. In D. 
melanogaster we showed for the first time longer chain LCB-P (upto d20) and 
also t18:0 LCB-P. Whereas in S.cerevisiae, we discovered unsaturated LCB-Ps 
d18:1
Δ11
 even though gene for sphingolipid desaturases are absent and we further 
validated and confirmed the biosynthesis of these species by stable isotope 
precursor supplementation  We also studied natural physiological variation of the 
LCB-Ps in healthy human plasma 360 individuals of Singaporean population 
across three ethnic groups (Chinese, Malay and Indian), there were significant 
differences for d18:0 and d18:1 LCB-P was observed between ethnic groups. The 
Chinese population showed the highest levels and d18:2 were significantly higher 
in female compared to male. These findings have immediate relevance for our 
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Lipidomics is the system level analysis of lipids and their interaction with other 
lipids, proteins and metabolites. Lipidomics is an emerging field mainly driven by 
rapidly advancing technologies such as mass spectrometry (MS). This rapidly 
expanding field complements other omics fields, like genomics, transcriptomics 
and proteomics to constitute the family of systems biology
1
.  Lipids show vast 
diversity in structure, and functions (Figure 1.1). Coordinated lipid metabolism 
(anabolism and catabolism) is a key molecular integrator for homeostasis, 
membrane structure, dynamics and signaling; any imbalances in these contribute 
to diverse phenotypes and pathological states.
2
  
In this thesis, current and new approaches used in lipidomics have been 






Figure 1.1. Lipid classes with important representative structure (adapted 
from Wenk, 2010)  
 
1.2 Lipidomic Analysis 
Mass spectrometry is the method of choice for lipidomic analysis because of its 
high level of selectivity, specificity for the identification of complex molecules in 
a mixture, and the high sensitivity in analyte quantification (below fmole amounts 
even in complex matrices).
1
  
However the success of mass spectrometry analyses fundamentally depends on 
good sample preparations and separation techniques (chromatography).
2
 
1.2.1 Sample preparation 
Extraction of lipids from complex biological matrices aims at removing 
interfering agents like proteins, sugars, amino acids and other small molecules. In 





preparation is often underestimated.
1
  There is no single extraction method that 
covers a total lipidome. There are mainly two extraction methods in lipidomics 
(Figure 1.2), A) liquid-liquid extraction (LLE) (single phase or two phases) and 




Figure 1.2. Schematic representation of the two extraction methods 
1.2.1.1 Liquid-liquid extraction  
The most widely used LLE for total lipid extraction was developed by Folch in 
1957 using chloroform/methanol (2:1) as the extraction solvents,
4
 and was further 
improved by Bligh and Dyer in 1959 by changing the sample to solvent ratios.
5
 
Lately, newer LLE methods were developed based on hexane/isopropanol (3:2), 
but due to poor extraction efficiency, they were not widely used.
6
 Similarly, 
another novel efficient method developed by Lofgren et al. based on butanol and 
methanol (BUME) was developed to extract total lipids from human plasma,
7
 
while Matyash et al. used methyl tertiary butyl ether (MTBE) with the advantage 
that the organic phase is in the upper part of the tube and can be easily collected.
8
 
These methods work relatively well for a wide variety of lipids but not enough for 
















some of the species are highly water soluble (such as LCB-Ps and 
glycosphingolipids),
9
 whereas others are hydrophobic (such as ceramides). 
Therefore, poor recovery or loss of some of these low abundance species can be 
experienced in two-phase separations. 
1.2.1.2 Solid Phase Extraction 
SPE methods are not well explored in lipidomics due to the chemical diversity of 
lipids. Popularly used methods are normal-phase based, such as silica, nitrile (-
CN), amine (-NH2) or diol groups to separate neutral lipids and phospholipids.
10
 




 and for 
total lipid extraction.
13
 However these SPE methods are not selective in capturing 
specific lipid molecules. 
There are several advantages of SPE over LLE with respect to specificity and 
selectivity: enrichment (by removing high abundant lipid molecules), high 
reproducibility, less consumption of solvents, different formats (cartridges, 96 
well plates, tips) which could be important for automated high-throughput 
extraction. 
Novel promising SPE technologies that are emerging in the lipid field are based 
on molecularly imprinted polymers, also called ‗MIP‘. Some of these 
methodologies have shown promising results for enrichment of sterol derivatives 






1.2.1.3 Molecularly imprinted polymers (MIP)  
Molecularly imprinted polymers are synthetic artificial receptors that specifically 
bind target analyte molecules or a related class of compounds. Molecular 
imprinting is a technique that is template (analyte analogue) directed and allows 
the design and synthesis of polymers with very well defined recognition sites. 
Molecular imprinting technology leads to the formation of 3 dimensional 
macromolecular structures by a process of polymerization that makes usage of a 
template molecule and a functional monomer for co-polymerization, in the 
presence of a crosslinker and an initiator in porogenic solvent.
17
 In this process, 
functional monomers are positioned spatially around the template and the 
positions are fixed by copolymerization with crosslinking monomers. The 
template is removed by thorough washing steps to disrupt the reversible 
interactions between template and monomers, leaving behind the imprint of the 
template.  The porous polymer matrix contains specific imprints or recognition 
sites that are stereochemically complementary to the template molecule, enabling 
the polymer to rebind the template molecule and its analogues (Figure 1.3). As a 
control a non imprinted polymer (NIP) is also synthesized, in the same way, 






Figure 1.3. Principle of molecular imprinting (1) self-assembly of template (T) and 
functional monomer (2) polymerization in presence of cross linked and initiator and (3) 




The template used during the imprinting is usually an analogue of the 
analyte molecule.
15, 22
 This is due to several reasons, like the risk of residual 
template leaking also called ―bleeding‖, that could interfere in the analyte 
detection. The choice of the right functional monomers (eg: acrylic acid, 
methacrylic acid acrylamide, 4-vinylimidazole, 1-(4-vinylphenyl)-3-phenyl urea 
etc.) is very important since they act as anchors interacting with the template. The 
importance of a crosslinking agent (eg: ethylene glycol dimethacrylate, 
divinylbenzene etc.) is due to their action in controlling the polymer morphology. 
The solvent used as a porogen during the imprinting process depends on the 
solubility of all the entities like monomer, template, initiator and crosslinker. The 
porogen also helps in the formation of large pores (hence the name porogen) in 
macroporous polymers to assure reasonable ‗flow through‘ properties of the 
resultant MIP; very common porogens are acetonitrile, toluene, chloroform, 
dichloromethane, etc. The amount of polymerization initiator (eg: 2,2‘-Azobis-
isobutyronitrile (AIBN)) added during the imprinting process plays a significant 




1.2.1.3.1 Steps in  MIP synthesis 










1.2.1.3.2 Applications of MIP 
MIPs are mostly used for sample preparations and separations (eg. Solid phase 
extraction (SPE), offline and online enrichment in chromatography columns) for: 
18, 21, 24-26
 








 Large structures like proteins33, cells34 





 drug delivery using MIP
38
 
Due to their properties, MIPs are also called ―artificial antibodies‖. However, 
there are several advantages of MIPs when compared to antibodies as selective 




range of solvents, at high temperature, and under mechanical stress.
39
 Moreover, 
they are easier to produce and can be reused several times without loss of their 




A chromatography with unique separation capability is important for the 
comprehensive analysis of very complex samples before introducing into the 
Mass spectrometer. There are several commonly used separation methods: thin-
layer chromatography (TLC), high-performance liquid chromatography (HPLC), 
gas chromatography (GC), supercritical fluid chromatography (SFC), and 
capillary electrophoresis (CE)
3
. As in this project we mainly used HPLC, a brief 
description of this technique is reported below. 
1.2.2.1 High-performance liquid chromatography (HPLC) 
HPLC is a commonly used separation technique in lipid analysis with high 
reproducibility and resolving capability. HPLC combined with mass spectrometry 




The two most popular chromatographic modes in lipidomics are called reverse-
phase (RP) and normal-phase (NP) according to the type of separation used. 
1.2.2.1.1 Reversed-phase chromatography (RP) 
In RPLC the separation of lipid species is based on hydrophobicity of the 
molecules (Cer from Glucer), the difference in fatty-acyl chains (example, fatty 




commonly used include C4, C8 and C18. The mobile phases used are non-
aqueous solvents (Isopropanol, Acetonitrile etc) in a gradient from lower to higher 
hydrophobicity for separation of the samples.
40-45
 
1.2.2.1.2 Normal-phase chromatography (NP) 
NPLC can separate different classes of lipids based on their polar head groups. 
The advantages over reversed-phase LC include the co-elution of internal 
standard and analytes (some internal standards used are short chains that elutes 
differently in RP) that allows ionization under identical solvent composition 
conditions in MS. NP has also advantages in separating isobaric compounds 
(example: phosphatidylcholine and sphingomyeline). The columns used are made 




Recently, a variant of NP has developed with the name of Hydrophilic interaction 
liquid chromatography (HILIC). HILIC uses hydrophilic stationary phase and 
reversed-phase type mobile phases; its mechanism is based on liquid-liquid 
partition, where molecules are eluted with increasing polarity, opposite to RP 
methods. Column materials used in HILIC are silica, amine, amide and diol. The 
starting mobile phase for HILIC is usually acetonitrile with a small amount of 
water. Use of a small amount of water helps in forming a water-rich layer on the 
surface creating a liquid-liquid extraction system. Ionic modifiers such as 
ammonium formate or ammonium acetate are used to control mobile phase pH 
and ionic strength that, contributing to the charge on the head group of lipids and 






1.2.2.1.3 Emerging LC technologies in lipid analysis 
With advancement of HPLC systems that works with higher pressures and LC 
column materials with smaller particle size (<2µm) the new LC systems called 
Ultra high performance liquid chromatography (UHPLC) are gaining lot of 
popularity in lipidomics, due to their higher resolution and shorter runtime when 
compared to traditional HPLC.
49, 50
 Besides UHPLC-MS there are also other 
technologies like nano-LC, (the inner diameter of the columns is reduced and 
flow rates are nl/min) where very little sample volumes are required and 
background chemical noise is greatly reduced to give better sensitivity.
51
 
HPLC-chip/MS is a novel nanoflow technology that has been originally 
developed and commercialized for proteomics applications. Chips are fabricated 
from layers of polyimide to form microfluidic channels, fluid inlet ports, column 
chambers, and an electrospray emitter. There are column channels for enrichment 
(40, 160, 500 nL) and separation (75µm ID, length of 43 mm or 150 mm) that can 
be packed with any standard column materials like RP C-18, C-8, C-4 and HILIC 
stationary phase. With HPLCchips, inline sample enrichment and separation can 
be achieved, no dead volumes are present, and the special nanoelectrospray tip at 




1.2.3 Mass spectrometry 
A mass spectrometric analysis fundamentally depends on the gas-phase ionization 




analysis, Electrospray ionization (ESI) and matrix-assisted laser desorption 
ionization (MALDI). 
1.2.3.1 Electrospray ionization (ESI) 
ESI produces gaseous charged ion molecules directly from a liquid by creating a 
fine spray of highly charged droplets in presence of high electric field. Since 
lipids are small molecules, the formation of singly charged molecules is mostly 
observed. In the positive ion mode free sphingoid bases, LCB-P, ceramides, 
glucosyl ceramides ionize as (M+H)
+
 and sphingomyelins carrying choline as 
head group (with a permanent positive charge on quaternary amine) are ionized as 
(M+)
+
. In negative ion mode ceramide-1-phosphate, LCB-P, sulfatides ionize as 
(M-H)
-
. A simple method to improve the ionization is by using ionic modifiers 
(such as formic acid, acetic acid, ammonium formate, ammonium acetate, lithium 
acetate, ammonia), usually added in small amounts in mobile phase solvents to 







, ammonium adducts (M+NH4)
+
. Adduct ions can also 




Samples are introduced into ESI MS either through direct-infusion (also called 
―shotgun approach‖) or with pre-separation in chromatography columns. There 
are new emerging technologies in shotgun applications, such as Chip nanospray 
(Advion nanomate) together with high resolution Mass spectrometers. This chip 
device contains a high-density array of nanospray nozzles that allows infusion of 






1.2.3.2 Matrix-assisted laser desorption ionization (MALDI) 
MALDI ion sources are normally coupled to time-of-flight (TOF) mass analyzers 
as it produces singly charged ions. Samples are often prepared by mixing a 
solution containing the analyte with a solution containing a matrix, usually a 
small organic molecule containing conjugated aromatic ring structures. The 
MALDI matrices can absorb the energy of laser and transfer the energy to the 
analyte. Commonly used MALDI matrices for lipid analysis are 2,5-
dihydroxybenzoic acid (DHB) and α-cyano-4-hydroxycinnamic acid (CHCA). 
The charging process can be induced by the addition of a proton (M+H)
+
 or loss 
of a proton (M-H)
–
 from the analyte or else it can form sodium, acetate and 
ammonium adducts. MALDI-MS has several disadvantages compared to ESI-MS 
like no liquid phase ionization and cannot couple to HPLC. However MALDI 
imaging of tissues is gaining popularity in lipidomics, as it can provide a dynamic 
spatial distribution of individual lipid molecules.
54, 55
 
Other ionization techniques used in lipid analysis 
Besides ESI and MALDI, other ionization techniques used are Desorption 
electrospray ionization (DESI), atmospheric pressure chemical ionization 
(APCI)
56
, atmospheric pressure photoionization (APPI). See ref for 
comprehensive description.
3
       
1.2.3.3 Tandem mass spectrometry 
Mass spectrometers can measure the mass of intact molecules or their fragments, 




experiments, a precursor ion mass is selected by the first mass analyser (MS1) and 
focused into a collision region preceding a second mass analyser (MS2). There are 
several mass analysers that can be arranged in different configurations like 
quadupoles (Q), time of flight (TOF), ion trap, orbitrap, and Fourier transform ion 
cyclotron resonance (FTICR). An inert gas such as argon, helium or nitrogen is 
generally introduced into the collision cell, where the collisions between 
precursor ions and the  gas at a fixed applied voltage, result in the dissociation of 
the precursor ion to generate product ions in  a process termed ―collision-induced 
dissociation‖ (CID). This process is also called MSMS. 
1.2.3.4 Tandem MS scanning modes  
1.2.3.4.1 Product ion analysis 
In the product ion scan mode the first mass analyser (MS1 or Q1, in Figure 1.5) is 
set to pass a single ion (m/z) of interest. This precursor ion is transmitted to the 
collision cell (hexapole collision cell, also referred to Q2) that is filled with inert 
gas for fragmentation, and operated to pass all product ions. The product ions are 
transmitted to the second mass analyser (MS2 or Q3), which scans across a wide 











 1.2.3.4.2 Precursor ion analysis 
In a precursor ion mode, the second mass analyser MS2 is set to pass the m/z of a 
unique specific product ion (for example m/z 264 is unique for sphingosine d18:1 
backbone). By scanning a wide range of precursor ions in MS1 and fragmenting 
all those precursor ions in collision cell, only a specific product ion will be 
detected in MS2. A precursor ion scan of m/z 264 for example allows the 
identification of all the d18:1 containing sphingolipids. This greatly reduces the 
background chemical noise coming from complex lipid mixtures. 
1.2.3.4.3 Neutral loss scans (NL) 
In this mode MS1 and MS2 mass analysers are scanned together, but the m/z that 
MS2 will pass is put to offset from MS1 by a fixed value that corresponds to the 




fragmented in collision cell and the offset masses are scanned constantly in MS2. 
This is an effective way to identify specific compounds in complex mixtures. For 
example, to identify glucosylated ceramides, as 162 is lost as a neutral mass in 
product ion scans, 162 is the offset in the MS2 for identification of specific 
compounds in neutral loss scans.   
1.2.3.4.4 Multiple reaction monitoring (MRM) 
In MRM mode, the first mass analyser MS1 is set to pass a specific precursor ion 
m/z, and, after fragmentation in collision cell by CID, a specific product ion m/z 
is set to pass through the second mass analyser MS2. Thus, in this mode, only ions 
that meet both precursor and product ion m/z conditions simultaneously will be 
reaching the detector. Therefore, MRM is a highly specific and sensitive detection 
method and multiple transitions can be monitored in a single MS run. 
1.2.3.5 High resolution Mass spectrometry 
Mass spectrometer such as quadrupole-Time of flight (QTOF) offers several 
advantages in mass resolution of up to 40,000 and mass accuracy of 5ppm for MS 
spectra and 10ppm for MSMS spectra, which is sufficient for measuring 
elemental compositions for lipids. Modern QTOF instruments have very high ion 
sampling capability and have very high scan rates, in which the product ion scans 
are very fast and quantitation can be done efficiently. With combination of 
retention time, accurate precursor mass and product ion spectra can be used for 
identification of novel lipid species in lipidomic analysis.
58, 59
 More advanced 




Fourier transform ion cyclotron resonance (FTICR) and LTQ-Orbitrap can offer 
even higher resolution and sub ppm mass accuracy.
60, 61
  
In this thesis we contributed with new advancements to the lipidomics field by 
using newly developed sample preparation procedures, based on MIP and chip 
nanoLC-MSMS, to discover new sphingolipid species. 
1.3 Sphingolipids 
Sphingolipids are a class of lipids with a common structural feature: an aliphatic 
amino alcohol as backbone known as ―sphingoid base‖ or ―long chain base 
(LCB)‖. They were discovered in 1884 in brain extracts and were named from 
‗Sphinx‘ because of their enigmatic nature. The sphingosine d18:1 [(2S, 3R, 4E)-
2-aminooctadec-4-ene-1,3-diol or (E)-sphing-4-enine)] is the major sphingoid 
base found in mammals. The LCBs can be acetylated on the amine with fatty 
acids to form ceramides, which can be further modified by various head groups to 
form sphingomyelins (SM), ceramide 1-phosphates (C1P), and 




1.3.1 Nomenclature  
There are different forms of LCBs in different organisms. The different LCBs 
structures are characterized by the hydroxylations number, chain lengths, 
branching, and unsaturations number and position. The nomenclature of LCBs 
takes into account the hydroxylation number,  reported as mono (m) for one, di 




bonds (with their position). For example Sphingosine d18:1, contains 2 
hydroxylations on 18C chain length and the position of double bond is at 4 with 
trans configuration, represented as 4E-d18:1 or d18:1
Δ4t
. The LCB modified by 
phosphorylation is represented as LCB-P or S1P. The ceramides are usually 
represented after LCB with semicolon or slash followed by carbon chain length 




1.3.2 Diversity of LCB 
Pruett et al. in their comprehensive in-depth review have introduced the amazing 
biodiversity of LCBs.
63
 There are more than 60 natural LCBs that have been 
reported.
62-65
 The most abundant LCB in mammals is sphingosine (d18:1), but 
other common variants are: d18:0 (precursor of d18:1), d16:1 in heart, d20:1 in 
brain, t18:0 in skin (also common in plants and yeast), d18:2 in plasma (also 
common in plants) and odd chain variants like d17 and d19 which can contain 
linear or branched chains. There are trace amounts of shorter chain LCBs reported 
in mammals, but these are very common in insects, such as Drosophila (d14, d16 
LCB).
66
 LCBs (in both free and bound forms) discovered in various organisms are 
represented in Figure 1.6b, Table 1.1.  Sphingoid bases with branched chains 
such as iso- and anteiso- configurations have been reported in sphingolipids of 
bovin milk and kidney,
67
 and atherosclerotic human aorta.
68
 They are also 
associated with Mammalian tissues through microflora (microorganisms) that are 
normal or pathogenic for example iso-d15:0 sphingoid base that is found in 






There are many more sphingoid bases or sphingoid base-like compounds that 
disrupts the sphingolipid metabolism such as serine palmitoyl transferase (SPT) 
inhibitors like myrocin/ISP-1 produced by fungi.
70, 71
 There is growing interests in 
the pharmaceutical potential for the drug development for many pathological 
conditions (such as cancer) based on these natural products, with the success of 





Figure 1.6.  Common LCB structures in various organisms. LCB d18:0, 
d18:1, d18:2, d20:1 and d16:1 are common in mammals. LCB d14:0, d14:1, 
d14:2, d16:0, d16:1 and d16:2 are common in Drosophila. LCB t18:0 is common 
in plants and yeast. LCB m18:0 is found in mammals due to mutation of enzyme 




























































1.3.3 De novo biosynthesis of Sphingolipids 
De novo sphingolipid synthesis (Figure 1.7) starts with the formation of 3-
ketosphinganine (3-keto-dihydrosphingosine) by condensation of serine (2 
carbons) and palmitate (16 carbons) through the action of serine palmitoyl 
transferase (SPT), which is the rate-limiting enzyme (genes SPTLC1-3 in 
mammals
74-76
, LCB1 and LCB2 in yeast
77, 78
 and lace in Drosophila
66
). SPT 
interacts with regulatory proteins for substrate selectivity; yeast SPT requires an 
additional protein Tsc3 for its optimal activity
79
, although there is no mammalian 
homologue for it. Mammalian SPT is regulated by two small SPT subunits, 
ssSPTa and ssSPTb.
80
 The substrates of SPT are usually palmitoyl-CoA (C16:0) 
and serine, but this enzyme can accommodate other longer or shorter chains fatty 
acyl-CoA. The SPT isoform SPTLC3 has a substrate preference
81, 82
 for 
myristoyl-CoA (C14) to produce d16 LCBs, very common in Drosophila.
66
 The 
d20 LCB is mainly found in brain sphingolipids and their production is 
specifically regulated by ssSPTb.
80
 Mutations on SPT can shift the preference for 
cosubstrate from serine to alanine to produce neurotoxic 1-deoxysphingolipids 
(example m18:0, Figure 1.6b).
83
  
The second enzyme in the pathway is 3-ketosphinganine reductase (also called 3-
ketodihydrosphingosine reductase); 3-ketosphinganine is reduced to sphinganine 
(dihydrosphingosine).  Sphinganine can be acylated to different dihydroceramides 
by a family of ceramide synthases (CerS) .
62
 The ceramide synthases genes lag1p 
and lac1p were found in S. cerevisiae and the mammalian homologue of lag1p, 




generate ceramide with d18:0/C18. In this family there are up to five additional 
CerS with distinct selectivity for substrates [CerS1 (C18), CerS2 (C22, C24), 
CerS3 (≥C24), CerS4 (C18, C20, C22), CerS5 (C16) and CerS6 (C14 and 16).84-88 





Figure 1.7. De novo sphingolipid biosynthesis pathways. Pathway (e.g. C18 
sphingoid bases) represented here is general for yeast, mammals and Drosophila. 
 
The next step in the pathway is the desaturation and hydroxylation of 
dihydroceramide to form ceramides and 4-hydroxyceramides (phytoceramides) by 
desaturases. There are two mammalian desaturases DES1 and DES2, reported to 
Serine
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have different functions. DES1 add the 4,5-trans double bond to make Cer, and 
DES2 hydroxylates position 4 to form phytoceramide (t18:0 backbone). DES2 is 
bifunctional as expression of mouse DES2 in S. cerevisiae (SUR2 mutants) 
resulted in the formation of both (E)-sphing-4-enine and 4-hydroxysphinganine.
91
  
DES1 is also present in Drosophila while in S. cerevisiae there is no gene 
encoding for desaturases. The phytoceramides are very common in yeast, as yeast 
contains a C4-hydroxylase encoded by the SUR2 gene to synthesize 
phytoceramides. The homology between DES2 and DES1 is much greater than 
that between DES2 and SUR2. The substrate for DES2 in mouse is 




In mammals, ceramide is a precursor for biosynthesis of complex sphingolipids 
like sphingomyelins (SM), ceramide-1-phosphate (C1P), galactosylceramide 
(GalCer), glucosylceramide (GluCer), which can be further modified with more 
complex sugars. Other forms include ceramide phosphoethanolamine (CerPE), in 
small amounts in mammals but very common in Drosophila. In yeast, 
phytoceramides are modified further to inositol phosphorylceramide (IPC), 




The ceramides are catabolised through deacetylation by ceramidases (CDase) to 
form sphingosine (LCB); ceramidases are categorized as acid, neutral and 
alkaline. In mammals the acid ceramidase is localized in the lysosomes. There are 




with ceramidase activity similar to mammalian neutral ceramidases. In S. 
cerevisiae the gene YPC1 encodes an alkaline ceramidase with dual activity, 
which catalyses both hydrolysis and synthesis of yeast phytoceramides.  YPC1 
homologues also encode alkaline ceramidases with substrate specificity towards 
dihydroceramide and only slightly for phytoceramide. Interestingly these enzymes 
do not hydrolyze the unsaturated mammalian ceramides.
89, 96, 97
   
 The LCBs formed from catabolism of ceramides can be recycled back or 
phosphorylated by the enzyme sphingosine kinase (SphK) to sphingosine 1-
phosphate (LCB-P). There are two forms of mammalian SphK called Sphk1 and 
SphK2.
98, 99
 Similarly in Drosophila there are genes with close homology to 
mammalian‘s, named SK1 and SK2.100 Also in S. cerevisiae, there are two genes 
encoding for sphingosine kinases, LCB4 and LCB5. Both the enzymes can use 
phytosphingosine, dihydrosphingosine or sphingosine as substrate with different 
affinities to form LCB-P.
101
 
The synthesized LCB-P can be reversibly dephosphorylated by sphingosine-1-
phosphate phosphatase to generate LCB and recycled back to ceramide. There are 
two genes, LBP1 and LBP2, encoding S1P phosphatases in S. cerevisiae. Based 
on the sequence homology with LBP1, the mammalian S1P phosphatase was also 
cloned in mouse.
102
   
Sphingosine-1-phosphate is irreversibly degraded by the enzyme S1P lyase at the 
C2-C3 bond to give phosphoethanolamine and fatty aldehyde. This is the only 




then converted to fatty acids while phosphoethanolamine enters the 
glycerophospholipid synthesis
103
. The first S1P lyase gene was characterized in S. 
cerevisiae, and then, based on the sequence homology, murine and human S1P 
lyases were cloned and characterized.
104, 105
 Also in Drosophila the S1P lyase 
gene (sply) is well characterized.
106
   
1.3.4 Diversity of LCB-P 
As discussed, LCBs show diverse chemistries across biological species and 
tissues.  Despite the presence of various non phosphorylated LCB precursors, 
little is known about the existence of LCB-Ps with different chemical and 
structural composition. The LCB-Ps identified in different organisms are reported 




Table 1.1. LCB diversity 
 
Note:  
 Numbers in the box are cited papers and the bracket delta followed by number refers to double bond position and c&t, cis and trans 
isomers 
 118 Human Skin, SPH shows d16:1 to d24:1, DHS shows up to d16:0 to d27:0 long chain bases and 6-hydroxy SPH d16 to d21  
 111 (Δ3) possible that it could be byproduct of acid hydrolysis 
 ‗m‘, mono hydroxy; ‗d‘, di hydroxy; ‗t‘, tri hydroxyl 
 
Table 1.2. LCB-P diversity
Free/bound LCB d14 d15 d16 d17 m18 d18 d19 d20 t18 t20 
double bonds 0 1 2 0 1 2 0 1 2 0 1 2 0 1 2 0 1 2 0 1 2 0 1 2 0 1 2 0 1 2 
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1.3.5 Mammalian LCB-P 
In mammals, LCB-Ps are mainly enriched extracellularly in blood plasma and are 
produced by erythrocytes, platelets and endothelial cells. The LCB-Ps produced 
by these cells derive from the catabolic process of shingolipids, where 
sphingomyeline leads to the formation of ceramide by sphingomyelinase, further 
processed to LCB by ceramidase. LCB is then phosphorylated by sphingosine 
kinases (SPHK1 or 2) to LCB-P (Figure 1.8a). The LCB-P levels in cells are 
tightly regulated not only by the biosynthetic enzymes, but also by the 
degradative enzymes like S1P lyase and phosphatases. Erythrocytes and platelets 
are exceptions, as they lack the S1P lyase or phosphatase activity, and they are the 
main source for the high levels of the LCB-Ps in blood.  Plasma contains high 
levels of d18:1 LCB-P (~1µM), whereas interstitial fluids like lymph contains low 
amount of the LCB-P, generating a gradient between blood and lymph.
127, 128
 In 
plasma the LCB-Ps are bound and transported by apolipoprotein M (65%) in 
high-density lipoprotein (ApoM HDL) and albumin (35%).
129, 130
  
1.3.5.1 LCB-P receptors and their signaling  
In mammals, most of the functions of S1P are extracellular through cell surface 
receptors. There are five S1P receptors (S1PR1-5) on the cell surface; these are all 
G protein-coupled receptors. These receptors bind S1P (d18:1) and dihydro S1P 
(d18:0) with high affinity and there is not much evidence for other endogenous 
ligands despite the diversity of LCB-Ps. S1PR1 was one of the first functionally 
identified and most studied receptor. It is ubiquitously expressed and its most 











Figure 1.8. Mammalian sphingolipid metabolism pathways and S1P receptor. 
(a)  The levels of blood LCB-P is mainly by catabolism of membrane 
sphingolipids like sphingomyelin. (b) S1PR1 crystal structure. (Adapted from 






This receptor has unique N-terminal helix folds, which caps the receptor and 
blocks the access of S1P to the binding pocket from the extracellular space. S1P 
could bind by entering laterally between helix I and VII within the transmembrane 
region of the receptor. The S1PR2 receptor is expressed ubiquitously and is 
mainly involved in S1P-induced cell proliferation, motility and transcriptional 
activation.
133
 The S1PR3 receptors are also expressed ubiquitously and participate 
in the regulation of angiogenesis and vascular endothelial cell function.
134
 S1PR4 
and S1PR5 are less widespread; S1PR4 is mainly expressed in lymphoid and 
hematopoietic tissues and S1PR5 primarily in the white matter of the CNS 
(central nervous system) and spleen.
135
 
1.3.5.2 S1P receptor modulator treatment in multiple sclerosis 
The immunomodulatory drug fingolimod (FTY720, Gilenya
TM
) is the first oral 
drug approved by USFDA (United States Food and Drug Adminstration) for 
treatment of relapsing forms of multiple sclerosis
72
, which is an inflammatory 
disorder associated with damage of nerve cells in brain and spinal cord, resulting 
in range of signs and symptoms.
136
 Fingolimod is a chemical derivative of 
myriocin, a fungal metabolite isolated from Isaria sinclairii,137 and a structural 
analogue of sphingosine (Figure 1.9). Similarly to sphingosine, fingolimod is 
phosphorylated in vivo to its active form become a structural analog of S1P.
138
 
The drug binds to S1PR1 and S1PR3-5. It downregulates surface expression of 
S1PR1 on lymphocytes and prevents the egress from lymphoid tissues reducing 











Figure 1.9. Fingolimod and fingolimod-phosphate are structural analogues of 
sphingosine and sphingosine 1-Phosphate. Fingolimod similar to sphingosine is 
phosphorylated by sphingosine kinases to become bioactive (Adapted from 
Brinkmann, 2010) 
 
The LCB-Ps in Saccharomyces cerevisiae and Drosophila melanogaster are 






1.4 Specific Aims and Objectives  
Current approaches in lipidomics largely aim to obtain a comprehensive coverage 
of several lipid classes but, at the same time, the information about low abundant 
bioactive lipids (e.g. LCB-Ps) is lost. LCB chemistry is known to be diverse but 
not clear if that is reflected in LCB-Ps. Here in this thesis, I developed novel 
approaches for better characterization of these metabolites.  
Main objectives of this project, 
 Technology development (Selective capture of LCB-Ps): 
 Introduction of a new solid phase material for selective capture of 
phosphate monoester lipids based on molecularly imprinted polymers 
(MIP) 
 Optimizing the conditions for MS analysis of a particular class of 
bioactive lipids called ‗long chain base phosphates‘ (LCB-P)  
 Applications: 
 Application of these enhanced workflows for the discovery of new 
LCB-Ps in various model organisms 
 To understand and validate the biosynthesis of novel LCB-Ps 
discovered in wild type or genetically modified model organisms like 
S. cerevisiae and D. melanogaster 
 To  understand the natural variation (baseline measurements) of LCB-
Ps in human plasma of healthy Singaporean populations (Chinese, 
Malay, Indian) 




Materials and methods 
2.1 Materials 
N-vinylimidazole; 2,6-bis-(bromomethyl) pyridine and ethylene glycol 
dimethacrylate (EGDMA) were purchased from Sigma Aldrich (St. Louis, MO). 
Dry acetonitrile used for synthesis was purchased from Merck. N,N
1
-azo-bis-(2,4-
dimethyl) valeronitrile (ABDV) was purchased from Wako. DMSO-d6 was 
purchased from Deuterio-GmbH (Kastellaun, Germany). EGDMA was purified 
by the following procedure prior to use. The received material was washed 
consecutively with 10% aqueous NaOH, water and brine. After drying over 
MgSO4, the purified compound was obtained by distillation under reduced 
pressure. 
1
H NMR spectra were recorded at 300 MHz otherwise mentioned. 
Elemental microanalyses were performed using a CHN-rapid HERAEUS 
Analyzer. 
All solvents for LC-MS analysis were LC-MS grade and were purchased from 
Fisher Scientific and Merckmillipore. Lipid standards: D-erythro-Sphingosine-1-
phosphate (S1P d18:1) and Isotope labeled Standard D-erythro-Sphingosine-1-
phosphate (
13
C2D2–S1P,) were purchased from Toronto Research Chemicals, D-
erythro-C17-Sphingosine-1-phosphate (S1P d17:1), 1,2-dimyristoyl-sn-glycero-3-
phosphocholine (DMPC), 1,2-dimyristoyl-sn-glycero-3-phospho-(1'-rac-
glycerol)(DMPG), 1,2-dihexadecanoyl-sn-glycero-3-phosphate (DPPA), 1-




phosphate (Cer-1P), D-glucosyl-ß-1,1' N-octanoyl-D-erythro-sphingosine (Glu-
Cer), N-heptadecanoyl-D-erythro-sphingosine (Cer), N-lauroyl-D-erythro-
sphingosylphosphorylcholine (SM) and (2S, 3S, 4R)-2-amino-1,3,4-
octadecanetriol-1-phosphate were purchased from Avanti polar lipids (Alabaster, 
AL, USA). Dioctanoyl Phosphatidylinositol (PI) was purchased from Echelon 
Biosciences (USA). Palmitoleic acid (
13
C16), Acetic acid, ammonium formate 
(HPLC grade), formic acid, adenine, uracil, tryptophan, histidine, arginine, 
methionine, tyrosine, leucine, isoleucine, lysine, phenylalanine, glutamic acid, 
aspartic acid, valine, threonine, serine, dextrose and Trimethylsilyl (TMS) 
diazomethane solution were purchased from Sigma-Aldrich (St. Louis, MO). 
Palmitic acid (7, 7, 8, 8-D4) was obtained from Cambridge Isotope. Difco
TM
 





peptone were from Becton, Dickinson company. Human blood 
for plasma was obtained from healthy volunteers (NUS-IRB Reference No. 04-
115) using EDTA as anticoagulant. Blood samples were centrifuged at 2200xg for 
15 min to isolate plasma and frozen at -80°C within 45 min of blood collection.  
2.2 Synthesis of IMP Monomer, Polymer and derivatization 
2.2.1 Synthesis of bis-imidazolium monomer  
A solution of 2,6-bis-(bromomethyl) pyridine (0.5 g, 1.88 mmol) and N-
vinylimidazole (0.35 ml, 3.76 mmol) in acetonitrile (25 ml) was refluxed 
overnight. To prevent polymerization, a spatula tip of sulphur was added to the 
reaction mixture. After cooling to room temperature, the solvent was evaporated 
Materials and Methods 
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to dryness under vacuum. The resulting solid was then redissolved in ethanol and 
precipitated out with the addition of diethyl ether, to afford the desire product 
(0.71 g) as a solid (83%). 
1
H NMR (300 MHz, DMSO) δ 5.43-5.47 (m, 2H), 5.64 
(s, 4H), 5.98-6.04 (m, 2H), 7.35-7.43 (m, 2H), 7.55- 7.57 (d, 2H), 7.87-7.88 (m, 
2H), 7.97- 8.02 (t, 1H), 8.24-8.25 (t, 2H), 9.67 (s, 2H); 
13
C NMR (75 MHz, 
DMSO) δ 52.73, 108.92, 118.70, 122.24, 124.11, 128.76, 136.16, 138.82, 153.15. 
Calculated C 45,06 %, H 4,23 % , N 15,45%; found C 43,26 %, H 4,81 %, N 
15,17%. 
2.2.2 Synthesis of IMP resin 
Bis-imidazolium monomer (1) (134 mg, 0.2975 mmol) and EGDMA (2) (2.25 ml, 
11.925 mmol) were mixed 1/1 into a 20 ml glass vial containing 10 ml of 
toluene/methanol. ABDV (25 mg, 0.097 mmol) was added and the solution was 
degassed for 10 min with N2. The polymerization tube was sealed and the mixture 
was kept at 50 ºC using a water bath for 24 hours and subsequently at 70 ºC for 4 
hours. The solid polymer was removed from the glass vial, roughly crushed and 
Soxhlet extracted with methanol for 48 hours. The crude product was further 
crushed and sieved to 25-50 m and sub-25 m particles. The former fraction was 
used as sorbent for solid phase extraction (Figure 2.1). 
 
Figure 2.1. Synthesis of IMP resin by thermal co-polymerization of bis-
imidazolium monomer (1) and EGDMA (2) using ABDV as initiator and 
methanol:toluene (1:1) as porogen.  
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2.2.3 Study of selective binding and elution of S1P 
To investigate the selectivity of the IMP resin for LCB-Ps, standard lipids were 
loaded and eluted in different conditions. The effect of various percentages of 
basic (1% triethyl amine) and acidic (1% trifluroacetic acid) solutions was 
investigated. Best selectivity and recovery were obtained when loading the 
resuspended sample in 1 ml isopropanol (in some cases acetonitrile was also used) 
and washing the resin sequentially with 1 ml isopropanol, 1 ml 
isopropanol/methanol (50/50). Elution was obtained with 2 x 0.8 ml 
chloroform/methanol/1% trifluoroacetic acid (49.5/49.5/1). This enrichment 
protocol was applied to all the analysed biological samples. The IMP resin wells 
can be reused after regenerating with 3 x 1ml methanol/acetic acid/water 
(60/30/10) and equilibrating with 3 x 1 ml loading solution before using again.   
2.2.4 Derivatization 
The obtained fractions were dried and reconstituted in 100 µl of methanol. 10 µl 
of TMS-Diazomethane were added and the sample incubated for 20 min at room 
temperature under gentle mixing on thermomixer at 750 rpm. The reaction was 
stopped by adding 1 µl of acetic acid. The derivatized samples were dried in 
speedvac and reconstituted in 100 µl of mobile phase before injecting into the LC-
MS system. 
2.2.5 Recovery study for Phosphomonoesters lipids 
To test the recovery rate from the IMP resin with the reported enrichment 
protocol, brain tissue extract obtained as described above was spiked with 
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standard DMPC (250ng), DMPG (100ng), Glu-Cer (100ng),SM (50ng), LPC 
(50ng), Cer (50ng), C8-PI (15ng), S1P ISTD (4ng), DPPA(50ng), Cer-1P (50ng), 
LPA (50ng) before homogenisation and loaded onto the IMP resin in 1 ml loading 
solution. The lipid content of 2 different fractions (flow through+wash and eluate) 
was measured by LC-MS before (for phosphate diesters and non-phosphorylated 
species detection) and after (for monoesters) derivatization with TMS. Recovery 
in flow through+wash and eluate was estimated as % of the lipids present in the 
loaded fraction. 
2.2.6 Offline enrichment of LCB-P in various biological matrices 
Ten (for plasma and lymph) and 20 (for tissues) mg of the IMP resin were dry 
packed in an empty 96 well plate (Agilent) with polypropylene filters at both 
bottom and top of the resin. Different protocols were optimized for selective 
capture of S1P and related species (as described before) with different solvents for 
conditioning, loading, washing, eluting and regenerating the resin (refer to earlier 
section study of selective binding and elution of S1P).  
2.3 Standard Preparation 
Main stock solutions of standards were diluted in methanol to a final 
concentration of 0.5 mg/ml for S1P (d18:1), 
13
C2D2–S1P (Internal standard) and 
S1P (d17:1). The stock solutions were further diluted in a concentration range of 
50-1000 ng/ml for S1P (d18:1) for validation experiments, while the Internal 
Standard was kept at a concentration of 200ng/ml or 400 ng/ml.  
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2.4 Protein Precipitation (single step methanol extraction) 
 10 µl Plasma (5µl for Lymph) were mixed with 10 µl ISTD (5µl ISTD for 
lymph) and 90 µl Methanol. The solution was shaken on a thermomixer for 20 
min at 4°C and centrifuged for 10 mins at 14000 rpm. 
2.5 Sample extraction from Mouse Plasma and Lymph 
All the mice colonies were maintained and sample (lymph, plasma and tissues) 
collection was carried out by Chung Hwee Thiam from Assis. Prof. Veronique 
Angeli Lab, Immunology programme, Center for life sciences, Singapore. 
Male Wild Type C57 BL/6 (WT) mice were obtained from the Jackson 
Laboratory (Bar Harbor, ME). All mice were maintained on a chow diet (18% 
protein and >5% fat, Harlan Teklad, Madison, WI) post wean until 6 weeks of 
age. Diet was then switched to a Western-type (21.2% fat and 0.2% cholesterol, 
Harlan Teklad) until mice were sacrificed at 22-28 weeks of age. Mice were 
maintained under specific pathogen-free conditions with free access to food and 
water in the Animal Housing Unit of the National University of Singapore. All 
studies were performed under protocols approved by the Institutional Animal 
Care and Use Committee (IACUC) of the National University of Singapore. 
Blood was drawn from the mice via cardiac puncture immediately after sacrifice 
and mixed with 50µl of 100mM EDTA. The blood-EDTA mixture was then 
centrifuged at 14000g, for 10 minutes at 4°C and the plasma was obtained from 
the supernatant for subsequent S1P extraction. Special care was taken to minimize 
red blood cells and platelets lysis throughout the whole process, avoiding 
aspiration of blood through fine needles. All mice were fasted overnight prior to 
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lymph collection to clear dietary lipids from the lymph fluid. 25µl of lymph fluid 
were crenulated from the cysterna chyli with the use of Extended Length Gel-
loading Pipette Tips (Neptune Scientific) and collected into a new Eppendorf 
tube. The lymph samples were centrifuged at 14,000g for 10 minutes at 4°C and 
the supernatant was obtained for subsequent S1P extraction. Subsequent protein 
precipitation was performed as previously reported. 
2.6 Validation 
2.6.1 Recovery studies for methanol extraction 
The recovery of S1P was determined by spiking the Internal Standard (ISTD) 
13
C2D2–S1P in human and murine plasma samples at two different concentrations 
(40 and 80 ng/ml, n=3) before or after lipid extraction. Extraction and 
derivatization of S1P was then performed according to the procedure described in 
materials and methods. The recoveries of ISTD were determined from the peak 
area ratios for the standard spiked before and after extraction, according to the 
formula (area before extraction/area after extraction)*100. The recovery for ISTD 
at concentrations of 40 ng/ml and 80 ng/ml was estimated to be 80.1±9.6% and 
87.9±9.5% in human plasma and 82.1±5.4% and 97.4±2.5% in murine plasma. 
2.6.2 Calibration Curves 
Calibration curves for the quantification of S1P in plasma were built with the 
standard addition method, 
140, 141
 using a double blank (lipids extracted from 
plasma samples without ISTD), a blank (lipids extracted from plasma sample with 
ISTD) and samples spiked with 8 different concentrations (5, 7.5, 10, 20, 40, 60, 
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80, 100 ng/ml) of S1P (d18:1) containing a fixed amount of ISTD (40 ng/ml). The 
results, in the interval 5-100 ng/mL, were satisfactorily fitted by linear equations 
in both human plasma (y=0.032x-0.128) and in mouse plasma (y=0.024x-0.038) 
showing regression coefficients values of 0.9993 and 0.9972 respectively. 
2.6.3 Precision and Accuracy 
Intra-day/inter-day precision and accuracy were determined by analyzing quality 
control (QC) samples, consisting of human plasma spiked with standard S1P 
(d18:1) at three different concentration levels: Low-QC (5ng/ml), Middle-QC 
(40ng/ml), High-QC (80ng/ml) and a fixed IS concentration of 40ng/ml. Five 
replicates for each QC were analysed during the same day or over 2 consecutive 
days, while a plasma lipid extract spiked with IS was used as blank, to subtract 
the area of the endogenous S1P when calculating precision and accuracy. All 
measurements gave a coefficient of variation (CV) below 15%, as recommended 
by the United States Food and Drug Administration (USFDA) in case of target 
compound analysis. 
2.7 Sample extraction from mouse tissues 
Lymph nodes (1 lymph node) and brain samples (2.5 or 5 mg) from each 
individual mouse were weighed and resuspended in 190 µl of methanol + 10 µl of 
ISTD  Samples were sonicated in water bath at 4°C for 30 min. After centrifuging 
at 4°C for 10 min at 14000 rpm, the supernatant was collected for enrichment.  
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2.8 Sample extraction from Drosophila melanogaster 
Adults up to 2 days old, fed on standard Bloomington semi-defined Drosophila 














) were collected, flash frozen in liquid nitrogen, and stored at -
80° C for up to about one week before extracting lipids. Extractions of LCB-Ps 
were done in triplicate. 5 flies for each experiment were weighed and, after 
addition of 10 µl ISTD (40 ng/ml), homogenised in 500 µl methanol by using a 
pellet pestle (Sigma). After addition of 500 µl methanol, the samples were 
sonicated for 1 h at 4°C. After centrifugation at 14000 rpm, 4°C, for 10 min, 
supernatant was collected and dried in speedvac. 
2.9 Saccharomyces cerevisiae cultures 
Yeast from frozen -80
o
C glycerol stocks was used for inoculating 5ml liquid 
precultures. Culturing conditions for S. cerevisiae (W303) were adapted from 
standardized protocols previously described
142
 (in triplicates) experimental 
cultures were set using precultured yeast, by diluting to OD600 nm 0.1 in 50 ml of 
respective media YPD (yeast extract 1%, peptone 2%, dextrose 2%) or Synthetic 
complete  media (SC, dextrose 2%, bacto yeast nitrogen base 0.67%, most of the 
amino acids listed in materials section] and grown in 250 ml culture flask at 180 
rpm at 30
o
C until OD600 nm~1 was reached. Then yeast cells were pelleted by 
centrifugation at 3000g in 50ml falcon tubes and pellet washed twice in milli Q 
water. After the last wash, supernatant was discarded and pellets were frozen in -
80
o
C and lyophilized over night to obtain the dry yeast cells. The dried cell pellet 
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was weighed for lipid extraction (discussed later in lipid extraction 
Saccharomyces cerevisiae section 2.9.4)
 
2.9.1 Media experiment 
S. cerevisiae (W303) was grown in YPD and SC media at 30
o
C and harvested at 
OD600 nm~1 is reached.  
2.9.2 Stable isotope labeled precursor supplementation 
Stable isotope labelled fatty acid [Palmitic acid (7, 7, 8, 8-D4) or Palmitoleic acid 
(
13
C16)] (0.01%) was dissolved in 1% tergitol final concentration in 150 ml of SC 
media. S. cerevisiae (W303) were grown in fatty acid supplemented SC media at 
30
o
C and harvested at OD600 nm~1 is reached. 
2.9.3 Growth phase experiment 
S. cerevisiae (W303) was grown in SC media at 30
o
C in triplicates, cells were 
harvested when OD600nm is reached 0.5 (lag phase); 1 (early logarithmic (log) 
growth phase); 3 (middle log phase); 4.5 (late log phase); 6 (stationary phase).  
2.9.4 Lipid extraction from Saccharomyces cerevisiae 
2.5 mg of lyophilized yeast (W303) were resuspended in 500 µl methanol and 
after addition of 5 µl ISTD (200ng/ml), homogenised with glass beads by 
vortexing for 2 min. After addition of 500 µl methanol, the samples were 
sonicated for 1 h at 4°C. After centrifugation at 14000 rpm, 4°C, for 10 min, 
supernatant was collected and dried in speedvac. The dried sample were loaded 
on to IMP resin and derivatised (as described in section Offline enrichment of 
LCB-P in various biological matrices and derivatisation) 
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2.10 Stable isotope labeled precursor supplementation in Caco2 cells 
Caco-2 cells (ATCC) were routinely grown and used between passages 15-20. It 
was maintained in  T75 flasks, in Dulbecco modified Eagle medium (DMEM), 
supplemented with 10% fetal bovine serum (FBS), 2mM L-glutamine, 100 U/mL 
penicillin/streptomycin and cultured at 37°C in a humidified atmosphere of 5% 
(v/v) CO2 in air. For the 
13
C16- labeling experiments, cells at 80% confluence 




C16 palmitoleic acid in 
ethanol was complexed with 1:1 molar ratio of fatty acid-free BSA in medium as 
described previously
144
 for final concentration of 0.05% (
13
C16 palmitoleic acid). 
After adding fatty acid the cells were harvested after 7 hours incubation. The cells 
were pelleted by centrifugation at 3000g for 10mins at 4
o 
C and the pellet was 
washed with PBS. For lipid extraction, the pellet was suspended in 1ml of 
methanol  after spiking the internal standards, sonicated for 30mins at 4
o 
C. The 
samples were centrifuged to remove proteins, obtained supernatant was dried and 
resuspened in 200µl methanol for IMP purification. For ceramide analysis, ‗flow-
through‘ was collected from IMP purification. 
2.11 Sample extraction from Human Plasma 
The protocols are reported and adapted from the Husna Begum‘s thesis, 2013.145  
―All 360 participants were of Singaporean nationality in equal proportions of 
Chinese (120), Malay (120) and Indian (120) ethnicities. Samples were collected 
from healthy individuals defined by the absence of major clinical diseases 
including diabetes and stroke. Participants were selected from the Singapore 
Consortium of Cohort Studies. Their age group was limited (40 to 69), with an 
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average age of 49 to 53 across the three ethnic groups. Higher compliance rates of 
females resulted in a 1.7:1 female:male ratio across all three ethnicities. Samples 
were collected at a fixed venue by trained phlebotomists over a period of seven 
months. Participants were asked to fast overnight for at least eight hours and 
samples were collected between 8 to 10 am in the morning. Blood collection is 
described in Material and methods section.
145
   
Background information of the participants was collected using the Singapore 
Consortium of Cohort Study official questionnaire. The comprehensive 50 page 
questionnaire included information on the participants‘ lifestyle factors 
(smoking), personal and family medical history, physical activity and social 
background. An intensive food frequency questionnaire was also included to 
gauge participants‘ dietary habits. This information was not analyzed in this 
study‖ (Husna B thesis, 2013).145 
2.11.1 Ethics Statement 
All healthy human plasma samples were collected in accordance to ethical 
guidelines and protocols approved by the National Health Group Institutional 
Review Board, Singapore. All participants who were approached for this study 
and agreed to participate in this study were required to provide written consent by 
signing on consent forms. 
2.11.2 Sample Collection and Processing 
10ml of whole blood samples were obtained in BD Vacutainer® plastic plasma 
tubes with EDTA as anti-coagulant by venipuncture. Plasma was processed by 
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spinning 10ml of fresh blood collected at 2200g for 15mins at 4 degrees using a 
swing-out bucket rotor centrifuge. Subsequently the plasma was transferred to 
5ml cryovials (Practical Mediscience). The plasma was frozen to 80°C.  
2.11.3 Quality control samples and sample analysis 
Pooled samples were employed as Quality Control (QC) to monitor technical 
variability. The samples were analyzed in two different sets. Set-1: 150 samples 
into 5 batches and set-2: 210 samples into 7 batches. All the Set-1 samples were 
analyzed in QTOF mass spectrometer (Agilent 6540) and Set-2 samples were 
analyzed in QTOF mass spectrometer (Agilent 6550).  
2.11.4 Data analysis 
All the statistical analysis was done by Duan xinrui and Li bowen. For ethnic, 
gender related differences were analyzed using student‘s t-test (two-tailed, 
p<0.05). Correlation between different LCB-P species were carried using 
Pearson‘s correlation in Microsoft excel.  Linear regression with type II ANOVA 
(two-tailed, p<0.05) in R and Statistical significance across ethnicity is reported in 
tabular format. 
2.12 Instrumentation 
2.12.1 LCB-P analysis 
All LC-MS/MS experiments were performed using Agilent 1200 series HPLC-
Chip systems connected to Agilent 6540 or 6550 Q-TOF and to Agilent 6490 
QQQ mass spectrometers. Two different types of chip were used for Reverse 
Phase and HILIC separations. The Reverse Phase Ultra High capacity Chip 
Materials and Methods 
43 
 
included a 500 nL enrichment column (5 µm particle size, 80 Å pore size) and a 
75 µm × 150 mm C18 analytical column (Agilent Technologies Corp., Santa 
Clara CA). A customised HILIC-chip containing Amide-80 stationary phase 
(Tosoh Bioscience, LLC. Montgomeryville, PA, 5 µm particle size, 80 Å pore 
size) was also prepared, including a 160 nL trapping column and a 75 µm × 150 
mm analytical column (Agilent Technologies Corp., Santa Clara CA). The 
Agilent 1200 series HPLC used a capillary pump for sample injection onto the 
Enrichment column and a Nano pump for separation. Solvents used for the 
Reverse Phase LC: 5% water in 95 % methanol with 5mM ammonium formate 
and 0.1% formic acid (solvent A), 50% methanol in 50% isopropanol with 5mM 
ammonium formate and 0.1% formic acid (solvent B). Analytes were eluted with 
the following gradient: 5%B to 20%B from 0 to 2 mins, 20% to 60% B from 2 to 
8 mins, 60%B to 100% B from 8 to 18 mins, 100% B from 18 to 23 mins, 5% B 
from 23.1 to 33 mins. The chip cube was operated with back flush mode and 
samples were injected through the enrichment column at 4 µl/min. The valve was 
switched immediately to place the enrichment column in line with analytical 
column at a flow rate of 400nl/min. The Agilent 6540/6550 quadrupole time-of-
flight (QTOF) mass spectrometer was operated in positive ion mode; electrospray 
voltage was set to 1600 V (Vcap), temperature 300°C, drying gas 4 L/min, 
fragmentor voltage 150 V. The instrument was operated in targeted MS/MS mode 
with MS acquisition rate of 1 spectra/sec and MS/MS acquisition rate of 2.0 
spectra/sec. Solvents used for HILIC HPLC: 50% acetonitrile in water containing 
25mM ammonium formate pH 4.6 (solvent A), 95% acetonitrile containing 
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25mM ammonium formate pH 4.6. The pH value was adjusted with formic acid. 
Analytes were eluted with the following gradient: 100% B from 0 to 1.5 mins, 
100 to 40% B from 1.5 to 8.5 mins, 40 to 30% B from 8.5 to 10.5 mins, 0% B 
from 11.5 to 13.0 mins, 100% B from 13.1 to19 mins. The chip cube was operated 
with back flush mode and samples were injected through the enrichment column 
at 4 µL/min. The valve was switched 1.5 mins after injection to place the 
enrichment column in line with the analytical column at a flow rate of 400 
nL/min. The instrument was operated in targeted MS/MS mode with MS 
acquisition rate of 2 spectra/sec and MS/MS acquisition rate of 2 spectra/sec. For 
the validation of the method, murine and human plasma samples were spiked with 
known concentrations of standard S1P d18:1 and ISTD (S1P-
13
C2D2) in the 
concentrations reported below. The Agilent 6490 triple quadrupole (QQQ) mass 
spectrometer was operated in positive for MRM mode (instrumental parameters 
and MRM transitions are reported in table S2) and negative for neutral loss (NL) 
scan mode; for NL of 60 m/z, electrospray voltage was set to 1580 V (Vcap), 
temperature 300°C, drying gas 4 L/min and collision energy of 25 V. In positive 
ion MRM mode, two product ions generated from the LCB-P precursors after 
fragmentation were monitored. The one at m/z 60 was used as a quantifier due to 
its high intensity and the one at m/z 113 was used as a qualifier, except in the case 
of phytosphingosines where 113 was used as a quantifier. These ions were present 
after fragmentation of all LCB-P species. The qualifier at m/z 113 represents the 
mono-methylated phosphate and was used to discriminate between penta-
methylated species generated by the derivatization reaction and the endogenous 
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ones containing an extra methylation on the long chain base. In negative ion NL 
mode, a neutral loss of 60 (due to the loss of triethylamine group) and formate 
adducts of the precursor ions were considered for the measurements. 
Quantification was performed according to the internal standard method, 
comparing peak areas of the sample to the ISTD. The method shows linearity in 
the physiological range that has been reported for S1P.  
2.12.2 Sphingolipids analysis in Drosophila melanogaster 
Sphingolipids analysis was done on Agilent 1260 UHPLC with 6460 QQQ mass 
spectrometer in positive MRM mode using reverse phase mode .The column used 
was C18 Eclipse plus RRHD  1.8 µm particle size, 2.1× 50 mm analytical column 
(Agilent Technologies Corp., Santa Clara CA). The Agilent 1260 series UHPLC 
used a quaternary pump for sample injection and separation. Solvents used for the 
Reverse Phase LC: 40% acetonitrile in 60 % water with 10mM ammonium 
formate (solvent A), 10% acetonitrile in 90% isopropanol with 10mM ammonium 
formate (solvent B). Analytes were eluted with the following gradient: 20 to 60% 
B from 0 to 2 mins, 60 to 100% B from 2 to 7 mins, 100% B from 7 to 9 mins, 
20% B from 9.01 to 10.5 mins. The Agilent 6460 triple quadrupole (QQQ) mass 
spectrometer was operated in positive for MRM mode (instrumental parameters 
and MRM transitions are reported in Appendix 8a), capillary  voltage was set to 
3500 V (Vcap), gas temperature 300°C, drying gas 5 L/min, nebulizer 45 psi, 
sheath gas temperature 250°C, sheath gas flow 11 L/min, and nozzle voltage 
500V. 
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2.13 Data acquisition and analysis 
All the mass spectrometer data were acquired on the Agilent mass hunter 
acquisition software. The data analysis was done on Agilent mass hunter 
qualitative software for MS, MSMS, neutral loss spectra extraction, and for 
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Results and discussion 
Chapter 3 
3.1 Lipidomic „deep profiling‟: enhanced workflows reveal novel LCB-Ps 
3.1.1 Development and optimization of MIP for phosphate monoester lipids 
Design and synthesis of functional monomer and synthesis of MIP was carried out 
by our collaborators Prof. Börje Sellergren, Dr. Sudhirkumar Shinde and Dr. 
Robert Sulc, MIP group, Malmö University, Sweden. 
 Phosphate is common among biological lipids and present in either 
monoester or diester configuration, with most biologically active lipids containing 
at least one phosphate monoester. S1P, C1P, LPA, PA and PIPs (Figure 3.1) are 
bioactive signaling molecules and are found in lower amounts in the biological 
matrix compared to phosphate diester and non-phosphorylated lipids.
115, 146
 Low 
molecular weight bis-imidazolium hosts have been extensively studied for 
recognition of inorganic phosphate.  Selection of functional monomers for the 
synthesis of MIPs able to isolate phosphate monoester lipids was based on the 
specific recognition for the dihydroxyphosphate residue by imidazolium groups 
(Figure 3.2) that contain hydrogen-bond donor sites.
147-149
 




Figure 3.1. Classification of phospholipids based on their phosphate 
esterification. Phosphate monoester lipids are mainly Sphingosine 1- phosphate 
and related species (LCB-Ps), Ceramide-1-phosphate (C1P)  related species, 
Lysophosphatidic acid (LPA) related species, Phosphatidic acid (PA) related 
species and Phosphatidylinositolphosphate related species (PIPs eg. PI (4) P). 
















Figure 3.2. Bis-imidazolium functional monomer and phosphate interaction. 
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The number of lipid species containing the dihydroxyphosphate residue that can 
interact with this MIP is small, allowing for an easier selection of the lipid species 
to capture and enrich. NIPs (Non imprinted polymers) were also synthesized, 
without using a template, as a control to compare their binding efficiency to 
MIPs. 
In the present study we used bis-imidazolium as a functional monomer 
synthesized by 2,6-bis-(bromomethyl) pyridine and N-vinylimidazol. 
Phosphatidic acid (1,2-Dipalmitoyl-sn-glycero-3-phosphate) was used as template 
for imprinting. Even if the target for our study was S1P, we did not use it as 
Template to avoid carryover (template bleeding). Ethylene glycol dimethacrylate 
(EDMA) was used as cross linker, N,N
1
-azo-bis-(2,4-dimethyl) valeronitrile 
(ABDV) as initiator of polymerization and toluene/methanol (1:1) as porogen. 
The ratios of template/functional monomer/cross linker used were 0.5:0.5:20. 
After pre-polymerization the polymerization was initiated by the initiator. The 
macroporous solid polymer formed was roughly grounded and sieved to 25-50 
µm particles. The imprinted polymer was thoroughly washed (to remove the 
template) initially with methanol in a soxlet extractor and then using methanol: 
acetic acid (70:30) in batch or on the empty 96 well SPE plate. The confirmation 
of template removal was monitored by mass spectrometry. Similar to MIP 
synthesis we also synthesized NIP without template for comparison. 
To evaluate the MIP and NIP difference, lipid standards representing various 
classes including S1P (target analyte) were loaded onto the polymers (Figure 
3.3). The ‗load‘, ‗flow-through‘ and ‗eluate‘ fractions were analyzed by liquid 
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chromatography-nanoelectrospray ionization mass spectrometry in positive (LC-
ESI-MS
+
) and negative (LC-ESI-MS
-
) polarity. Loading using Isopropanol or 
Acetonirtile showed similar binding for S1P without loss in the flow-through. The 
‗flow-through‘ fraction included phosphate diesters and non phosphorylated 
lipids. Elution-1 (E1 IPA: methanol (1:1)) triggered release of other non specific 
bound lipids. Elution-2 (E2 1% TEA) showed no release of S1P and Elution-3 (E3 
1% TFA) showed a complete release of S1P. With our optimized conditions we 
observed that the behavior of MIP and NIP was similar. We hypothesize that the 
imprinting efficiency on MIP is not complete and it could be due to the poor 
solubility of the Template [Phosphatidic acid (PA)] in the porogen solvent (not 
more than 0.5mg/ml). NIP showed clear specificity for phosphate monoesters (eg: 
S1P) without any previous imprinting. 
 In the current research in imprinting field not much attention has been 
paid to NIPs, as their binding properties are apparently difficult to predict. NIP 
are non-specific binders of various classes of analytes, while MIP should target 
molecules very specifically.
150
 However this current view has been challenged by 
recently published papers.
151
 The new hypothesis suggests that the presence of the 
template during MIP synthesis only acts to enhance binding properties that 
already exist in NIPs. The lack of high specificity of NIPs was turned to our 
advantage to target various classes of lipids containing phosphate monoesters with 
different chain lengths, unsaturations and other modifications like hydroxylations. 
NIP can be simpler, less expensive and very quick to produce when compared to 
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MIP. For this reason we only used NIP [also referred to as Imidazolium polymer, 
IMP] in our method validation and application. 
 
Figure 3.3. MIP/NIP behavior for various classes of lipids representing 
phosphate monoester lipid, phosphate diester lipids and non phosphorylated 
lipids. Extracted ion chromatograms (EIC) of the load, flow-through, and eluate 
fractions as analyzed by liquid chromatography-nanoelectrospray ionization 
quadrupole time of flight mass spectrometry in either positive ionization modes. 
MIP/NIP selectively captures phospho-monoester lipids (Ceramide-1-phosphate, 
C1P; sphingosine-1-phosphate, S1P; phosphatidic acid, PA; lysophosphatidic 
acid, LPA). Lipids with no phosphate (Ceramide, Cer; Glucosyl-Ceramide, Glu-
Cer) and those with phosphorus bound in diester configuration 
(phosphatidylcholine, PC; sphingomyelin, SM; lysophosphatidylcholine, LPC; 
phosphatidylglycerol, PG; and phosphatidylinositol, PI) do not efficiently bind to 
MIP/NIP and are recovered mainly in the flow through fractions instead. Elution-
1 (E1) of S1P was studied by substituting methanol (Solvent effect), elution-2 
(E2) was carried out by substituting 1% triethylamine (effect of Base) and finally 
with elution-3 (E3) was tested with 1% trifluroacetic acid (effect of acid). Elution-
3 fraction was the best condition to release the bound S1P. The behavior of 
MIP/NIP was similar.  
Control
Flow Through
E1 (Effect of Solvent)
E2 (Effect of Base)
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3.1.2 Recovery of Phosphate Monoester lipids 
A complex lipid mixture (Figure 3.4a), derived from a methanol extraction of 
murine brain tissue and thus expected to contain phospho-diester and phospho-
monoester lipids in addition to lipids without phosphate, was mixed with lipid 
standards (see methods) and loaded (in isopropanol) onto the immobilized 
imidazolium polymer. The ‗load‘, ‗flow-through‘, ‗wash‘ and ‗eluate‘ fractions 
were analyzed by liquid chromatography-nanoelectrospray ionization mass 
spectrometry in positive and negative polarity. All components with either no 
phosphate or with diester phosphates in their structures were recovered in the 
flow-through and wash fractions (Figure 3.4b, 3.4c). Acidification of the solvent 
system (chloroform/methanol, 1% trifluoroacetic acid; see online materials) led to 
the quantitative elution of phospho-monoester lipids (Figure 3.4b, 3.4c; 
Appendix 1). Therefore, this new IMP resin can bind phospho-monoesters and 
can be used to separate them from complex biological mixtures. 
This enrichment step is beneficial for the following MS analysis in terms of 
improvement of detection of phospho-monoesters, due to a lower suppression of 
other compounds possibly coeluting during a common LC separation and to the 
removal of other small molecules with a similar molecular weight that could be 
identified as LCB-Ps. Note, that we did not evaluate the specificity of this 
material, for example, for the discrimination of sulfate (which closely resembles 
phosphate in charge and geometry). This fractionation does not require any 








Figure 3.4. Substantially improved detection of LCB-P via an analytical 
workflow using phospho-monoester capture and derivatization.(a) Methanol 
extracts from different types of starting materials were loaded onto an 
imidazolium polymer (IMP) after protein precipitation (see Methods for detailed 
protocol). (b) Extracted ion chromatograms (EIC) of the load, flow-through/wash 
and eluate fractions as analyzed by liquid chromatography-nanoelectrospray 
ionization Quadrupole Time of Flight mass spectrometry in either positive (left 
panel) or negative (right panel) ionization modes. (c) IMP selectively captures 
phospho-monoester lipids (Ceramide-1-phosphate, C1P; sphingosine-1-
phosphate, S1P; phosphatidic acid, PA; lysophosphatidic acid, LPA). Lipids with 
no phosphate (Ceramide, Cer; Glucosyl-Ceramide, Glu-Cer) and those with 
phosphorous bound in diester configuration (phosphatidylcholine, PC; 
sphingomyelin, SM; lyso-phosphatidylcholine, LPC; phosphatidylglycerol, PG, 
and phosphatidylinositol, PI) do not effiently bind to IMP and are recovered in the 
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In a second step of method optimization, we decided to neutralize the negative 
charge of the zwitterionic LCB-P by derivatization with 
trimethylsilyldiazomethane (TMS-diazomethane), a commonly used methylating 
reagent.
153
 Methylation conditions were optimized using synthetic d17:1 S1P 
standard (Figure 3.5a), and the reaction products were characterized by LC-MS 
(Figure. 3.5b and c). Incubation of S1P standard in methanol+TMS-
diazomethane at 25ºC for 20 min yielded 95% tetra-methyl-S1P (Met4-S1P) and 
5% penta-methyl-S1P (Met5-S1P, Figure 3.5b), with no other reaction products 
detected. This derivatization step led to a sensitivity gain in positive mode MS of 
approximately 25–30fold compared with the non-derivatized S1P (Figure 3.5b), 
possibly explained by a more effective ionization of the methylated form, which 
carries a permanent positive charge on the amine group (Figure 3.5a, 
tetramethylated-S1P). Application of this derivatisation method for human Plasma 
LCB-P species revealed that their relative abundance was conserved after the 











Figure 3.5. Molecular structures of standard d17:1 S1P before and after 
derivatization with TMS-diazomethane. (a) Two different methylated 
derivatized structures are generated, one containing four methyl groups (top) and 
one containing five methyl groups (bottom). Methylated moieties are highlighted 
on red background color. (b) Chromatographic peaks of S1P d17:1 before (left) 
and after derivatization (right) recorded with the same LC-MS (positive mode) 
conditions. After derivatization, the tetra-methylated form represents 95% of the 
reaction product judged by the relative intensities of the ion chromatograms. (c) 
High resolution product ion analysis (using collision induced dissociation) of the 
tetra-methylated (top) and penta-methylated (bottom) forms. The precursor m/z is 
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Figure 3.6. Effect of TMS derivatization on LCB-P species distribution in 
human plasma. Full scan Quadrupole-Time of Flight mass spectrum of LCB-P 
species found in the same human plasma sample before (black) and after (red) 
derivatization with TMS-diazomethane (both samples were IMP purified). The 
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3.1.4 Validation  
By introducing and optimizing the above two steps (phospho-monoester capture 
via IMP and derivatization with TMS), we (i) improved the signal intensity of 
LCB-Ps derived from plasma by ~60-fold compared with LC-MS alone (Figure 
3.7);(ii) eliminated the carry-over effects commonly encountered with LC-MS of 
native LCB-Ps
154
 ; (iii) reduced matrix interference that could suppress LCB-Ps 
ionization or be considered erroneously as a specific signal when using low 
resolution MS. 
 
Figure 3.7. Two-step analytical enhancement using IMP enrichment (~2-fold 
increase in signal intensity, and importantly, removal of matrix interference) and 
TMS derivatization (~30-fold increase in signal intensity) leading to substantially 
improved detection of long chain base phosphates (LCB-P) with different 
aliphatic compositions (e.g. the di-ene form of S1P, LCB-P d18:2) in human 



















































This last experimental improvement is particularly important in very complex 
samples, as in murine brain (see interfering ions in Figure 3.8 that could 
compromise the reliability of the analysis) or whole fly extracts, where, without 





Figure 3.8. Effect of IMP resin on LCB-Ps detection. Extracted ion 
chromatograms representing the LCB-Ps identified murine brain, before (-IMP) 
and after (+IMP) the IMP enrichment step. Note the different scales in intensities 
between panels (-IMP) and (+IMP) IMP enrichment also eliminates co-eluting 
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The aforementioned characterizations involved nanoelectrospray ionization and 
high-resolution MS after chromatographic separation of the mixtures by 
Hydrophilic Interaction Chromatography (HILIC) built into a customized 
microfluidic chip. This was important to improve the co-elution of S1P standards 
and endogenous LCB-Ps for qualitative (Figure. 3.9) and quantitative 
characterizations of new LCB-P species. Indeed, few high-resolution mass spectra 
of LCB-Ps have been published, possibly because of the low signal intensities that 
hamper the precise characterization of ion peaks. The intrinsic characteristics of 
the HPLC chip contributed to the high sensitivity (nanospray ionization) and 
reproducibility (increased spray stability) of these studies. As both the enrichment 
and analytical columns present inside the chip were based on HILIC resins, the 
most hydrophobic molecules could be depleted from the sample by initially 
loading on the enrichment column before switching to the analytical and starting 
the elution process. This step further decreased matrix suppression effects. 
 
Figure 3.9. +MRM Elution peaks for the derivatized LCB-Ps in human plasma. In 
the inset, the elution profiles (normalized intensities) are represented, showing a retention 
time increase with increasing unsaturation and decreasing chain length of the molecules 
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This new detection method was further validated according to US Food and Drug 
Administration guidelines for bioanalytical methods.
155
 The calibration curves 
were built by standard addition to plasma and showed linearity in the 
physiological range. The interday %CV were <6%, and interday %CV were 
<15% (Figure 3.10a and b).  
a. calibration curves 







b. Intraday/interday precision and accuracy for S1P in Human Plasma 
 
Figure 3.10 Validation (a) calibration curves for derivatized S1P standard in 
human and murine plasma. (b) Intraday/interday precision and accuracy for S1P 
in Human Plasma 
 
 
Human Plasma Murine Plasma 
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3.1.5 Application of validated method and identification of novel LCB-Ps 
  We next extended our analysis to various biological species known to 
have different LCB (and thus possibly also LCB-P) inventories.
63
 When 
fragmented by collision-induced dissociation (CID), the derivatized d18:1 
13
C2D2-
S1P standard (m/z 440) yielded three product ions, indicated as A–C. Originating 
from the methylated amine group (fragment A at m/z 60; Figure 3.11a) and 
methyl-phosphate (fragment B at m/z 113), both A and B ions are expected to be 
invariant for different LCB-Ps, while the same was not true for ion C (m/z 328), 
which originated from the aliphatic portion. Indeed, when LCB-Ps from plasma 
were analyzed, the C fragment yielded m/z values as characteristic for d18:2 
(Figure 3.11b), d18:1 (Figure 3.11c), d18:0 (Figure 3.11d) and d16:0 in a lipid 
extract from Drosohphila melanogaster (Figure 3.11e).  
This product ion information, collected using a high-resolution Time of flight 
mass spectrometer with high mass accuracy (<5 ppm), provides a firm basis for 
targeted approaches using tandem-MS. Scanning for neutral loss of m/z 60 
(methylated amine group, fragment A) using a triple quadrupole mass 
spectrometer (with otherwise comparable analytical conditions) is a convenient 
mode to rapidly reveal LCB-Ps. Human plasma gave rise to strong signals from 
the d18 series (Figure 3.11f), including the newly discovered 18:2 derivative 
(HCCO adduct at m/z 478.1, Figure 3.11f) never described previously to our best 
knowledge (discussed in detail in chapter 6; natural variation of LCB-Ps in human 
plasma).  
 




Figure 3.11. Discovery and characterization of LCB-Ps in complex mixtures from 
diverse biological species (a) Collision-induced dissociation product ion mass spectra (in 
positive ionisation mode) of TMS-derivatized synthetic stable isotope standard (d18:1 
13
C2D2-S1P, m/z 440, diamond symbol) yielded expected ions at m/z 60 (fragment A), 
m/z 113 (fragment B) and m/z 328 (fragment C). The former two fragments are expected 
to be invariant for LCB-P with different aliphatic compositions which is indeed the case 
as shown for corresponding product ion spectra of LCB-P d18:2 (b), LCB-P d18:1 (c) 
and LCB-P d18:0 (d), all derived from extracts of human blood plasma, and d16:0 (e) 
from whole fly extract. , thus allowing for identification by targeted tandem mass 
spectrometry (Appendix 2). Targeted mass spectrometric analysis based on scanning for 
neutral loss of the methylated amine fragment (m/z 60) allows for determination of LCB-
P pattern in extracts derived from human plasma (f) and D. melanogaster (g and h). 
Sphingosine-phosphate lyase (sply in Drosophila) is the key enzyme in the irreversible 
degradation of LCB-P. Deletion of this gene in Drosophila leads to an accumulation of a 
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The S1P lyase is the key enzyme involved in the irreversible degradation of S1P; 
its impaired function in D. melanogaster (sply
05091
) leads to an accumulation of 
LCB-Ps.
109
 With a starting sample of only five flies, we demonstrated a 200-fold 
accumulation in not only d14 and d16 (the major LCB-Ps in Drosophila), but also 




 when compared 
with wild type (Figure 3.11g, h). Genetic background effects were controlled for 
by also analyzing changes in heterozygous animals, that resulted from crossing 
between sply
05091
 and a control strain, w
1118
 (wild type). Heterozygous sply
05091
/+ 
showed much less extreme changes than sply/sply, suggesting that the differences 
in sply/sply were indeed due to the mutation rather than the genetic background 
(discussed in detail in chapter 5, LCB-Ps in D. melanogaster) .  
Finally, we established multiple reaction monitoring (MRM) conditions 
(Appendix 3) for quantification of LCB-Ps in extracts from different biological 
origins (Figure 3.12a) with a limit of detection of 0.3 fmol on the column at a 
signal-to-noise (S/N) ratio of 120 and 20 with and without IMP, respectively, in 
human plasma (Appendix 4). The overall levels measured for d18:1 S1P and 18:0 
SA1P in murine and human plasma corresponded well with previously published 
values.
156
 Further, d18:2 LCB-P was present at levels comparable to SA1P 
(Figure 3.12a). Lymph nodes (but not lymph fluid) are devoid of this form of 
LCB-P (Figure 3.12a), which could be biologically relevant for the regulation of 
immune cell function in gradients of LCB-P
127
. We show for the first time that 
baker‘s yeast (S. cerevisiae) contains LCB-P with double bonds (Figure 3.12a) in 
addition to the reported fully saturated LCB-P (discussed in detailed in section 
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chapter 4; LCB-Ps in S. cerevisiae). We have identified, characterized (coelution 
with standard, extact mass, product ion analysis), and quantified thirteen LCB-P 
species not described previously and seven LCB-P not known to be present in the 
analysed biological samples, doubling the number of the known LCB-Ps (Figure 
3.12b). Although there is high confidence in the chemical identity of the newly 
described LCB-Ps based on comparisons with standards (d17:1, d18:1, 
13
C12D2 
d18:1 S1P) and on quantifier to qualifier ratios (see paragraph 3.16), we could not 
unambiguously define structures (position of the second double bond for example 
in d18:2 LCB-P in plasma and in D. melanogaster; discrimination between odd 
chain vs. methyl branched LCB-P). Despite this, ―deep profiling‖ is a promising 
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Figure 3.12. Quantification of LCB-P in complex mixtures from diverse biological 
species. (a) Quantification using MRM (list of MRM in Appendix 3) of LCB-P in 
mammalian blood plasma and lymphatic system, as well as extracts from model 
organisms, and mammalian cell lines (b) LCB-P species detected in this study. Dark blue, 
new LCB-P not described so far in the literature; light blue, LCB-P not known to exist in 
the respective biological species/tissue; gray, LCB-P previously described and measured 
with comparable results in this study and LCB-P (black) not detected in our method but 
described in literature.   
a 
b 
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3.16 Using quantifier/qualifier ion ratio to understand biodiversity of LCB-P 
To better identify the different LCB-P species, we used quantifier and qualifier 
ratios, a common concept in many MRM experiments for identification and 
quantification of compounds. The Quantifier (Quan) used in our MRM method is 
the most intense peak (fragment-A) in the fragmentation spectra and the Qualifier 
(Qual) (fragment-B) the second most intense peak (Figure 3.11a and Figure 
3.13a). We plotted this quant/qual ratio (Figure 3.13b) for the LCB-P d18 to 
understand how modifications on the aliphatic chain influence the Quan /Qual 
ratios in different model organisms. 
Some useful observations obtained from quantifier/ qualifier ratio analysis are 
reported below: 
 d18:0 LCB-P showed the same quant/qual ratio (1.4) in all organisms. 
 d18:1Δ4 LCB-P in all the organisms showed the same quant/qual ratio 
(3.3) except for S. cerevisiae (1.4) (discussed in more detail in chapter 4), 
suggesting that the double bond is in a different position.   
 d18:2 LCB-P showed the same quant/qual ratio (3.4) only for human and 
mouse but not in D. melanogaster (5.8). We hypothesize that the second 
double bond position in d18:2 is not the same across the species. D. 
melanogaster contains also LCB-P d14:2 and d16:2 in high abundance and 
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 LCB-P t18:0 is phytosphingosine-1-phosphate and is found in yeast, plants 
and mammalian skin sphingolipids. The presence of one hydroxylation 
influences significantly the quant/qual ratio (0.4). 
 
Figure 3.13 Quantifier to qualifier ratios. (a) Extracted ion chromatogram 
(EIC) of MRM for yeast LCB-P d18:1 and t18:0, human plasma d18:1 for 
Fragment A (60m/z; quantifier) and B (m/z113; qualifier) relative area ratio. (b) 
Plot of quantifier vs. qualifier ratios for all the LCB-P 18 series in different 
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4.1 LCB-Ps in Saccharomyces cerevisiae 
4.1.1 Background 
The reported LCB-Ps in Saccharomyces cerevisiae are mainly 
dihydrosphingosine 1-phosphate and phytosphingosine 1-phosphate. There are no 
reports of unsaturated LCB-Ps (eg. d18:1 LCB-P) as no sphingolipid desaturases 
genes are present in S. cerevisiae. In mammalian cells LCB-Ps have been 





activation of extracellular receptors. But the S.cerevisiae genome does not include 
any gene correspondent to cell surface receptors for LCB-Ps. Any role for LCB-
Ps in the physiology of S. cerevisiae must then be intracellular.  To clarify the 
functions of LCB-Ps in S. cerevisiae the genes for S1P lyase and phosphatase can 
be knocked out, leading to accumulation of large amounts of LCB-Ps. In these 
conditions cells are either nonviable or growing very slowly. A similar 





4.1.2 Identification of unsaturated LCB-P in S. cerevisiae 
Even if there are no previous reports about unsaturated LCB-Ps, with our deep 
profiling analysis, we managed to identify for the first time in S. cerevisiae 
(W303) d18:1, d20:1 and t20:1 LCB-Ps (Figure 4.1a). We further characterized 
the newly identified compounds by high resolution MS/MS and compared the 
MS/MS spectra of the LCB-P d18:1 from S. cerevisiae with that of LCB-P 
d18:1
Δ4
 from human plasma. The product ion spectra show a similar 
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fragmentation pattern; the only difference is in the ratios between fragments A 
and B (Figure 4.1b and c). This could suggest that the position of the double 
bond is not Δ4. Moreover, the discovery of LCB-P t20:1 indicates that the double 
bond cannot be in Δ4 due to the hydroxylation in the same position. To exclude a 
possible influence of the growth media composition on the presence of these new 
LCB-P species, S. cerevisiae was grown in both standard YPD and synthetic 
media (SC), and the LCB-P molecular species content was compared.  All the 
different LCB-Ps were present in S. cerevisiae grown in both culture media 
(Figure 4.1d) but their amounts were different; d16:0 and d20:1 LCB-P were 2 
fold higher while d18:1 and t20:1 LCB-P were 10 fold higher in the YPD 
compared to SC media. At this point we cannot draw any conclusion from these 
observations, possibly the rich medium (YPD) contains a variety of lipids in trace 
levels, that may be used as exogenous fatty acids for sphingoid base 
production.
160
 Could the precursor for unsaturated LCB-P be unsaturated fatty 
acids? Since the only desaturase (Ole1 gene) present in S. cerevisiae is delta 9 
desaturase for fatty acid. Ole1 expression changes with nutrients in media for 
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Figure 4.1. Discovery, identification and characterization of unsaturated LCB-Ps in 
S. cerevisiae (W303, OD
600
=1) (a) neutral loss scans of m/z 60 showing the diversity of 
the LCB-Ps in yeast. Peaks in red represent  unsaturated novel LCB-Ps. (b) Product ion 
scans of m/z 436.31 (M
+
) in both human plasma (d18:1
Δ4
) and S. cerevisiae (d18:1
Δ?
). (c) 
Comparison of the quantifier/qualifier [area (m/z 60) /area (m/z113)] ratio between 
human plasma and S. cerevisiae d18:1 LCB-P. (d) Comparison of the quantitative levels 
of the LCB-Ps in S. cerevisiae grown to OD
600
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4.1.3 Stable isotope labeled precursor supplementation 
To find out what could be the source of unsaturated LCB-Ps, we searched for 
desaturase genes in S. cerevisiae; the only desaturase present in the genome is 
encoded by the ole1 gene and is a delta 9 fatty acid desaturase. To verify the 
possibility that SPT could use an unsaturated fatty acid substrate in the first step 
of the sphingolipids biosynthesis, we added a stable isotope labeled palmitic acid 
[C16:0 (7, 7, 8, 8-D4)] to the growth media at a concentration of 0.01% in tergitol 
(1% final concentration in media). We observed by neutral loss scan analysis that 
the labeled plamitic acid was incorporated into the LCB-P d18:1 (m/z 484, 
M+HCOO
-
), d18:0 (m/z 486, M+HCOO
-
) and t18:0 (m/z 502, M+HCOO
-
) 
(Figure 4.2a). These results indicate that the double bond present in d18:1 LCB-P 
is added to the precursor plamitic acid through an enzymatic process.  In the next 




) at a 
concentration of 0.01% in tergitol (1% final concentration). The results showed 
incorporation of palmitoleic acid into LCB-P d18:1 (m/z 496, M+HCOO-) 
(Figure 4.2b), showing that in the reaction catalyzed by SPT for the formation of 
3-ketosphingosine, an unsaturated fatty acid can be used as a substrate. These 
results also support the idea that the d18:1 in S. cerevisiae is different from human 
plasma d18:1
Δ4
 LCB-P. The double bond could be in delta 11, as 16 carbons come 
from palmitoleic acid (C16:1
Δ9cis
) and 2 carbons from serine to form d18:1
Δ11cis 
(Figure 4.2c). These results were further validated by measuring the 
quantifier/qualifier ratios of the endogenous d18:1
Δ11
 of S. cerevisiae and of 
labeled d18:1
Δ11cis
 generated after supplementing the media with palmitoleic acid. 
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Both showed a similar ratio around 1.4 (Figure 4.2d), suggesting a possible 













Figure 4.2. Understanding biosynthesis of unsaturated LCB-P in S. cerevisiae 
(W303) by using stable isotope labeled fatty acid precursors. (a) Neutral loss scan of 
m/z 60 on samples supplemented with palmitic acid (7, 7, 8, 8-D4) and compared with 
control in SC media. (b) Neutral loss scan of m/z 60 on sample supplemented with 
palmitoleic acid (
13
C16) compared with control in SC media. (c) Proposed biosynthetic 
pathway for LCB-P d18:1 synthesis in S. cerevisiae. (d) Comparison of the 
quantifier/qualifier ratio of labeled LCB-P d18:1(m/z 452.3>60 and 113) with 
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4.1.4 LCB-Ps in different stages of yeast growth 
The relationship between the levels of different LCB-Ps and different growth 
stages of yeast was then examined (Figure 4.3a). S. cerevisiae (W303) was 
grown in the SC media and samples were collected at several time points 
representing different stages in the growth curve. After analysis by both neutral 
loss scan (for profiling) and MRM (for accurate quantification), reproducible 
trends were measured (Figure 4.3b and c; Appendix 6). In the lag phase of the 
growth, more than 50% of the total LCB-Ps was saturated. The content of 
saturated species decreased in the log phase and reached a lower stable level in 
the stationary phase. The d16:0 LCB-P was the most abundant LCB-P in lag 
phase but showed a 10 fold decrease after the transition to the stationary phase. 
The unsaturated LCB-Ps production is also higher in lag phase, decreasing during 
the log phase and becoming undetectable in the stationary phase. The 
phytosphinganine-1-phosphate (t18:0 LCB-P) is always maintained at constant 
levels throughout the different growth phases, however the longer chain t20:0 
LCB-P increases linearly by 8 fold after lag phase. Similar observations by Lester 
et al.
162
 showed that as the cells enter the stationary phase the total concentration 
of LCB-Ps is increased by 50%. The major increase was observed in the long 
chain LCBs (t20:0). The increase in the LCBs, LCB-Ps and particularly t20:0 
during diauxic shift represent at least in part a stress response, as a similar 
increase has been shown in separate studies during heat shock. The Tsc3 subunit 
of SPT is the most influential intrinsic factor in the accumulation of LCB t20s, as 
the levels of these species drop by 80% in post-diauxic tsc3 mutant cells. It is still 
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an important question how this LCB t20s arise and block mechanisms of stress 
resistance and survival in stationary phase.
162
  














Figure 4.3. LCB-P levels at different stages of S. cerevisiae (W303) growth. (a) 
Growth curve (OD
600
) in SC media (n=3).  (b) Relative percentage plot of all the LCB-Ps 
at different growth stages. (c) Profile spectra by neutral loss scan of m/z 60, clearly 
showing changes in LCB-P profiles at different points of the growth curve (refer to 
supplementary figure 1 for quantitative plots). 
S. cerevisiae
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Also the observation of higher levels of shorter chain LCB-P and unsaturated 
LCB-Ps in lag phase till middle log phase could also have important function in 
regulation of cell proliferation. This opens important question of their 























5.1 LCB-Ps in Drosophila melanogaster 
5.1.1 Background 
The sphingolipids in D. melanogaster are unique compared to mammalian cells 
and yeast. The LCBs are mainly d14 and d16 as compared to d18 and d20 in 
mammals and t18/d18 and t20/d20 in yeast. In Drosophila the shorter chain 
length of sphingoid bases may have different biophysical properties and 
biological functions compared to long chain sphingoid bases
163
. Sphingolipid 
biosynthesis in D. melanogaster starts with the condensation, catalyzed by the 
enzyme Serine palmitoyltransferase (SPT), of serine and fatty acyl-CoA (laurate 
C12:0 or myristate C14:0) to form 3-ketosphinganine. The 3-keto sphinganine  is 
then reduced to dihydrosphingosine. The dihydrosphingosine is N-acylated to 
dihydroceramide by a family of ceramide synthases (CerS) that uses a restricted 
subset of fatty acyl-CoAs. The dihydroceramides are finally desaturated to 
ceramides by a delta4 desaturase (Des-1). The ceramides can then be deacylated 
to sphingosine by the enzyme ceramidase (CDase). Sphingosine is either recycled 
back for ceramide formation or phosphorylated by sphingosine kinases (SKs) to 
S1P (LCB-P). LCB-Ps can either be dephosphorylated back to their precursors by 
S1P phosphatase and be recycled for sphingolipid formation or irreversibly 
degraded by the S1P lyase (Sply), which cleaves LCB-Ps into 
phosphoethanolamine and fatty aldehydes. Phosphoethanolamine can then be 
used for the synthesis of Phosphatidylethanolamine (PE), while the fatty aldehyde 
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is used for fatty acid synthesis. The step catalyzed by the lyase is the only exit 
point for a sphingolipid metabolic pathway and is of crucial importance. The 
LCB-P act as extracellular ligand for S1PR1-5 receptors in mammals or inside the 
cell independently of S1PRs. The S1P binding to receptors regulates functions 
like angiogenesis, lymphocyte egress, cardiac development. However Drosophila 
lacks S1PRs and it is then a good model for studying intracellular functions of 









 The two double bond containing 
LCB-P, called sphingodiene-1-phosphate was first identified and characterized by 
Fyrst et al.
109
. The position of the two double bonds was determined to be at 4 and 
6 in LCB. There are no genes identified in regulating this second bond addition in 
flies
109
. The sphingodienes have been reported to be present before in other 











 showed in a study on S1P lyase null mutants (Sply
05091
)  of D. 
melanogaster that in these conditions there is accumulation of both LCB-Ps and 
LCBs (d14 and d16) and that  these mutants show abnormal flight muscles 
development and apoptosis in reproductive organs. Egg-laying is diminished in 
females and spermatogenesis is defective in males. Along with their well-known 
bioactive functions, LCB-Ps are also important intermediates in the sphingolipid 
to glycerolipid conversion pathway.
164
 In Drosophila S2 cells, sphingolipid 
intermediates are required for the regulation of fatty acid biosynthesis, through 
their ability to inhibit the cleavage of the sterol regulatory element binding protein 
(SREBP).
103
 SREBP activity in cells is blocked by the addition of palmitate in cell 
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culture medium but not by sterols or other fatty acids.
103, 165
 These results indicate 
that palmitate must be converted to PE to inhibit SREBP, and that this conversion 
occurs through the sphingolipid pathway as shown in (Figure 5.1), but the authors 
of the paper do not show any evidence of sphingoid bases d18 in Drosophila to 
support their conclusions.  
 
Figure 5.1. De novo synthesis of sphingolipids in Drosophila. Enzymes 
involved in biosynthesis 1. Serine palmitoyltransferase (SPT), 2.  3-keto 
dihydrosphingosine reductase, 3. ceramide synthase (CerS), 4. sphingosine 
desaturase (Des-1), 5. Ceramidase (CDase), 6. Sphingosine kinase (SK1, SK2), 7. 
S1P phosphatases, 8. S1P lyase (sply) 
5.1.2 Discovery of novel LCB-Ps  
All the fly stocks and gene knockout experiments were carried out in the lab of 
Assoc. Prof Rachel Susan Kraut, Division of Molecular Genetics & Cell Biology, 
Nanyang Technological University (NTU), Singapore. 
 After analyzing  2 days old wild type adult flies (wt
1118
) our results showed that 
males contain LCB-Ps in higher abundance in comparison to female flies (Figure 
5.2a); this could be explained by the fact that the S1P lyase gene expression in the 
female flies is higher (Figure 5.2e). When analyzing S1P lyase KO mutant in D. 
melanogaster (Sply
05091
), we could detect an accumulation not only of d14:0 and 
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d16:0 (the major LCB-Ps in D. melanogaster), but also of d15, d17, d18, d19, 
d20, t18 and t20 LCB-Ps (Figure 5.2b and c), that have never been reported 
before to be present in flies. A 3 fold increase in Sply males and a 10 fold increase 
in Sply females was observed for d14 LCB-Ps when compared to wild type flies, 
while d16 LCB-Ps were increased by 50 fold in  males and 150 fold in females 
(Figure 5.2b and c). These data could suggest a preferential affinity of the lyase 
for d16:0 LCB-Ps. Another interesting insight from the data is that the LCB-P 
levels in male and female Sply mutant flies are supporting the observation of a 
differential expression of S1P lyase in wild type flies (Figure 5.2d and a). We 
also detected the presence of t18:0 and t20:0 LCB-Ps in Sply mutants. As 
phytosphingosines have never been detected before in D. melanogaster, we 
characterized the newly found species by accurate mass and tandem mass 
spectrometry, and compared the fragmentation pattern to both the t18:0 LCB-P 
commercial standard and also with the t18:0 LCB-P (Figure 5.2f) from 
S.cerevisiae. As the correspondence was high and there are no genes reported for 
the hydroxylation of sphingoid bases in D. melanogaster, we hypothesized that 
the observed t18:0 and t20:0 LCB-Ps could be introduced with the diet, based on 
yeast and plant extracts, and absorbed in the gut.  
In Sply mutants the d18 LCB-Ps are the second most abundant class after d16 
LCB-Ps, while in wild type flies d14 LCB-Ps are the most abundant followed by 
d16 LCB-Ps (Figure 5.2a, d). This observation suggests a higher efficiency and 
specificity of the S1P lyase in the degradation of longer chain LCB-Ps in wild 
type conditions. 





Figure 5.2. LCB-Ps in wild type and sply mutant flies (male and female; for raw 
data refer Appendix 7a and b) (a) LCB-Ps distribution in male and female wild type 
flies (mean and SD). (b) LCB-Ps distribution in male and female sply mutant flies (mean 
and SD). (c) and (d) LCB-P profiles in wild type vs. sply mutants in both males and 
females (mean and SD). (e) Gene expression levels of lyase in adult male and female 
wild type flies (flyBase database; www.flybase.org). (f) Product ion scan profiles of 
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5.1.3 d18 LCB incorporation into ceramides 
We also showed that d18 LCBs are incorporated into ceramide species by product 
ion scan (Figure 5.3a) and MRM scans, both in wild type and Sply mutant flies 
(Appendix 8a-f).The fatty acid length in d18 ceramides is shorter; the longest is 
C22, compared to d14 and d16 ceramides that incorporate also C26 and C24. The 
identification of d18 sphingolipids is important as it also supports the findings of 
Dobrosotskaya et al..
103
 According to this study the regulation of SREBP by 
palmitate through the sphingolipid pathway can only occur if d18 sphingoid bases 
are present. The authors of that paper never reported their presence but our results 
can support their conclusions. 
As observed for LCB-Ps, wild type male flies showed higher abundance of 
overall ceramides levels (Cer,OH-Cer, OH-GluCer GluCer, PECer) when 
compared to female flies, while the Sply mutants showed similar levels in males 
and females (Figure 5.3b, c; for subspecies refer Appendix 8c and d). Wild 
type and Sply mutant male flies showed no significant difference in the overall 
ceramides level, except for some of the subspecies like Cer d14:2/20:0, 
d14:2/24:1, d16:2/20:0, d16:2/22:0, d18:1/20:0, d18:1, 22:0; Glucer d16:2/20:0, 
16:2/22:0; and PECer d16:2/20:0 (Figure 5.3d; for subspecies refer Appendix 
8e),  however Sply mutant female flies showed a generally significant increase in 









Figure 5.3. Ceramides in wild type and sply mutant flies (male and female) (a) 
Product ion scan of Ceramides corresponding to m/z 518.5 [(-H2O) M+H] showed the 
simultaneous presence of  three different species with d14:2 (m/z 206.19), d16:2 (234.22) 
and d18:2(262.25) sphingoid bases and ceramides with m/z 566.6 (M+H) included 
different species with d14:1(m/z 208.20), d16:1(m/z 236.23) and d18:1(m/z 264.26) 
sphingoid bases respectively. (b) Abundance of different ceramide class in male and 
female wild type flies (Appendix 8c). (c) Abundance of different ceramide class male 
and female sply mutant flies (Appendix 8d). (d) Abundance of different ceramide class 
distribution in male (wild type vs. sply mutant) flies (Appendix 8d). (e) Abundance of 
different ceramide class distribution in female (wild type vs. sply mutant) flies 
(Appendix 8f). Note: Glucosyl ceramide (Glucer), hydroxylated Glucosyl ceramide (OH-
Glucer), phosphatidylethanolamine ceramide (PECer), hydroxylated phosphatidylethanolamine 
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5.1.4 Identification of modified LCB-Ps 
Our deep profiling method also revealed other new LCB-P species that we think 
could be generated by hydroxylation and oxidation of the common forms. The 
retention behavior of these species in HILIC chromatography showed a stronger 
retention compared to non-modified LCB-Ps (Figure 5.4a and b). For example, 
the extracted ion chromatogram (EIC) of d17:0 LCB-P included two additional 
peaks with longer retention times (Figure 5.4b). The tandem MS analyses on 
these peaks in high resolution mode showed similar A and B fragments compared 
to d17:0 LCB-P and a mass shift was only observed in fragment C (sphingoid 
backbone). We analyzed the same samples without derivatisation to rule out 
artifacts (Figure 5.4a and b; -Derivatization and +Derivatization) and the same 
molecular species were still present. These novel LCB-P forms represent around 
10 % of the total LCB-Ps. In Figure 5.4d, we generated hypothetical formulas for 
the detected species based on the accurate mass and retention behavior (for 
example addition of oxygen on the sphingoid moiety increases retention times on 
HILIC). Similar modifications on the sphingoid moiety were reported recently by 
Auray-Blais et al. and Boutin et al. in patients with Fabry disease, a lysosomal 
storage disorder caused by the deficiency of α-galactosidase A that results in 
glycosphingolipid accumulation in tissues.
166-169
 In another study, Karaca et al.
170
  
showed an effect of S1P lyase deficiency on  the lysosomal activity, due to 
accumulation of intracellular S1P. These recent publications support the 
involvement of accumulated sphingod base containing lipids in different 
















A B C 
d15:0 396.284 C19H43NO5P 396.287 7.5 na 60.080 112.998 284.292 
d15:2 (+32), d15:3(+34) 424.247 C19H39NO7P 424.245 4.0 +O2, +H2O2 60.080 112.999 312.252 
d16:0 410.301 C20H45NO5P 410.302 2.4 na 60.083 112.999 298.309 
d16:0 (+16), d16:1 (+18) 424.280 C20H43NO6P 424.282 4.0 +O, +OH 60.080 112.999 312.288 
d17:0 424.317 C21H47NO5P 424.318 3.0 na 60.080 112.999 312.324 
d17:1 (+32) 454.291 C21H45NO7P 454.292 2.2 +O2 60.080 112.999 342.298 
t18:0 454.327 C22H49NO6P 454.329 4.4 na 60.080 112.999 342.333 
d19:0 452.346 C23H51NO5P 452.349 6.6 na 60.080 112.999 340.355 
d17:2 (+32) 452.274 C21H43NO7P 452.277 6.6 +O2  60.080 112.999 340.282 
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LCB-P d17:0 (C21H47NO5P)+  
LCB-P d16:1 (+OH) /LCB-P d16:0 (+O) (C20H43NO6P)+












pathologies and they suggest a possible role of newly identified forms as 
biomarkers of the pathological condition.  


























Figure 5.4. Identification of novel modified LCB-Ps. (a) MRM base peak chromatogram of 
Sply mutant LCB-Ps before (-) and after (+) derivatization (b) Extracted ion chromatogram of 
Sply mutant LCB-P d17:0 with MRM transition 366.3>250.2 (- derivatization) and 424.3>60 
(+derivatization) chromatogram showing two additional peaks in higher retention time. (c) MSMS 
spectra of the modified LCB-Ps with close m/z ratio to LCB-P d17:0 (d) Summary table showing 
the modified LCB-Ps with experimental m/z, empirical formula, theoretical m/z, mass error (parts 
per million, ppm) and proposed modifications. 
d 




6.1 Natural variation of LCB-Ps in Singaporean population  
6.1.1 Background 
Circulating lipids have important roles in many biological pathways and 
consequently contribute to the risk for many pathological conditions like 
metabolic diseases or disorders.
171-173
 Specific lipids have been used for a long 
time as clinical markers for diagnosis, assessment, and prognosis of pathological 
states or drug treatment evaluations.
174-176
  
The natural variation of metabolites is influenced by many factors like genetics, 
age, gender, ethnicity etc.
177-180
 The lipidome variation in the individual or in a 
population is not known. Recently genome-wide association studies (also called 
GWAS) have identified numerous genomic regions that influence clinically 
relevant lipid metabolites.
181-183
 In a study by Hicks et al.
181
 on the circulating 
sphingolipids in healthy European population, 318,237 single-nucleotide 
polymorphisms (SNPs) were correlated with levels of circulating sphingomyelin 
(SM), dihydrosphingomyelin (Dih-SM), ceramide (Cer), and glucosylceramide 
(GluCer) lipid species measured in 4,400 individual subjects across diverse 
European populations.  They observed strong associations in 7 genes functionally 




We measured the biological variation of LCB-Ps in the healthy Singaporean 
population. This work is part of a larger study, the integrative Omics platform 
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(iOmics) that was initiated in 2010 and involves research teams in the area of 
genomics, transcriptomics and lipidomics.
184
 This platform was established to 
provide a descriptive analysis of the natural physiological variation between 
healthy individuals in Singapore across Chinese, Indian and Malay ethnicities. 
This is the first study looking at biological variation in a unique Asian population, 
which represents most of the Southeast Asian ethnicities. Part of the work 
presented in this thesis is based on the lipidomics platform that targets LCB-Ps 
(d18:0, d18:1, d18:2, d16:1) across three ethnic groups, as an extension to work 
previously done covering major lipid classes (Husna PhD thesis).
145
 In this study 
we will be looking at ethnic/gender related variations and discuss possible genetic 
link. We also attempted to identify the double bond position in LCB-P d18: 2, 
which we reported for the first time to be present in human plasma, through stable 
isotope labeled precursor supplementation experiments in Caco-2 cell lines 
(human colon carcinoma cells). 
6.1.2 Ethnicity related variation in LCB-P 
The levels measured for d18:1 and d18:0 LCB-Ps are within the previously 
reported ranges in healthy human populations. The data was analyzed by pairwise 
comparisons across the different ethnic groups using students‘s t-test (two-tailed, 
p<0.05) and plotted as ―Beeswarm‖ plot. There was a strong association between 
ethnicity and levels of d18:1 and d18:0 LCB-P, particularly with Chinese when 
compared to Indians and Malay populations.  A significant difference in d18:1 
and d18:0 was also present when comparing the Indian to the Malay population. 
An interesting observation was that the newly discovered d18:2 LCB-P showed 
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no ethnic associated biological variations. Moreover d16:1 LCB-P was only 
significantly different between Chinese and Indian populations (Figure 6.1a and 
b).  These two observations confirm that d18:1 and d18:0 belong to the same 
synthetic pathway, while d18:2 and d16:1 are probably generated from different 
precursors. This is important especially for d18:2 LCB-P, as its biosynthetic 
















Ethnicity d18:0 d18:1 d18:2 d16:1 
Chinese 0.207±0.087 0.978±0.352 0.150±0.044 0.035±0.010 
Indian 0.173±0.083 0.839±0.364 0.157±0.044 0.040±0.010 
Malay 0.141±0.046 0.673±0.199 0.144±0.034 0.038±0.010 
 
Figure 6.1. Ethnicity dependent variation. (a) Ethnic related trends for LCB-P 
species represented as Beeworm plots, plotted as concentration (µM) across 
ethnicity (Chinese, Indian and Malay in Singaporean population). (b) Absolute 
concentrations (µM) of LCB-Ps in different ethnic groups [mean and standard 
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6.1.3 Gender associated variation in LCB-P 
No significant gender associated variation in d18:1 and d18:0 LCB-P 
concentrations were found across all ethnic groups. A significant associated 
gender difference in lipid levels was observed for d18:2 LCB-P in Chinese and 
Malay, but not in Indian population.  Furthermore, d16:1 LCB-P was significantly 
higher in levels in Chinese females when compared to males (Figure 6.2).  
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Figure 6.2.  Gender related variability. Gender related trends for LCB-P species represented as Beeworm plots, 
plotted as concentration (µM) in (Chinese, Indian and Malay in Singaporean population) against gender (Female vs. 
Male). p-value; ns p>0.05, *p≤0.05, **p≤0.01, ***p≤0.001, ****p≤0.0001. 
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6.1.4 Correlation between different LCB-P species 
When considering the complete dataset, a strong positive  Pearson‘s correlation185 
between the d18:1 and d18:0 LCB-P (r = 0.93) was found (Figure 6.3). This 
could be explained by the fact that d18:1 derives from d18:0. However, the 
correlation between d18:1 and d18:2 LCB-P (r = 0.67), and d18:0 and d18:2 (r = 
0.64) is only moderate. A weak correlation was present between d16:1 and d18:1 
or d18:0 LCB-Ps (r = 0.23 and 0.15), while a moderate correlation was observed 
between d16:1 and d18:2 LCB-P (r = 0.61). The weak correlation between d16:1 
with d18:1 and d18:0 could be due to the fact that the biosynthesis of d16 
sphingoid bases is a distinct route, using myristate as a precursor instead of 
palmitate.
82
 This can be considered for d18:2 and is discussed in detail in 
paragraph 6.1.6. 
 
Figure 6.3. Correlations across different LCB-Ps, represented by Pearson‟s 
correlation coefficient (r). Note: ≤0.35 low where weak correlations, 0.36 to 
0.67 moderate correlation, 0.68 to 0.9 strong or high correlation, and 0.9 to 1.0 
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6.1.5 Linear regression analysis 
Linear regression analysis was performed to study the association between LCB-
Ps and demographic parameters including age, gender, ethnicity and Body Mass 
Index (BMI). BMI was found to be associated significantly with d16:1 and d18:2 
(Table 6.1). 
Table 6.1. Linear regression analysis 
 ANOVA (P values) 
LCB-P d18:0 d18:1 d18:2 d16:1 
Age 0.550 0.867 0.480 0.675 
Gender 0.234 0.342 0.081 0.087 
Ethnicity 3.164e-12*** 5.932e-14*** 0.044* 0.006** 





 has shown that LCB-Ps not only function as bioactive lipid 
molecules, but also as an important intermediate of the sphingolipid-to-
glycerolipid metabolic pathway. In their study, they reported that yeast (HFD1) 
and the Sjogren-Larsson syndrome (SLS)-causative mammalian gene (ALDH3A2) 
are responsible for conversion of the S1P degradation product hexadecenal (fatty 
aldehyde) to hexadecenoic acid. The absence of the ALDH3A2 in CHO-K1 
mutant cells has shown abnormal metabolism of S1P or hexadecenal to ether-
linked glycerolipids.  
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From our results we observe higher levels of the d18:1 and d18:0 LCB-Ps in 
Chinese when compared to Indian and Malay populations, thus it is important to 
consider genetic varation (example SNPs) in enzymes of sphingolipid metabolic 
pathway. Futhermore, HDL is the major carrier of S1P in blood, thus it is also 
important to consider the measurement of LCB-Ps in HDL particles in these 
populations. Previous reports on Singaporean population have shown higher 
mortality rates from ischemic heart disease in Indians when compared to other 
populations. This could be due to their higher prevalence of traditional 
cardiovascular risk factors, including serum cholesterol, lower HDL cholesterol, 
and higher rate of diabetes.
186, 187
 
6.1.6 Identification of double bond position in d18:2 LCB-P 
The position of double bonds within lipid molecules affects their structure and 
reactivity, with important implications in their biological function. The structure 
of the sphingoid base d18:2 which is the second most abundant LCB
115
, was 
initially identified by Renkonen et al.
117
 in human plasma sphingomyelins. The 
structure corresponded to d-erythro-1,3-dihydroxy-2-amino-4-trans-14-cis-
octadecadiene (d18:2
Δ4trans,14cis
) and this identification was later supported by 
other groups
188
. However, so far there are no reports of identification of any gene 
or enzyme in mammals involved in the addition of a second double bond to 
LCBs. The identification of the position of double bonds and their configuration 
is very relevant for functional studies. There are five different S1P receptors that 
are supposed to only bind d18:1 and d18:0 LCB-P with high affinity but there are 
no studies  that tested the binding of other structural forms present in vivo.
135
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 We attempted to characterize the position of the double bonds in the d18:2 LCB-
P by several different methods, like dimethyl disulphide (DMDS)
189
 adducts 
formation and ozone reaction. The DMDS is a popular reagent for locating double 
bond positions due to its excellent mass spectrometric properties and simple 
preparation. Moreover the reaction is sterospecific, making it the most suitable 
technique for distinguishing cis and trans forms. Our results showed that the 
d18:1 LCB-P did not react with DMDS in delta4; this is probably due to the 
presence of the hydroxyl group at carbon-3 that interferes with the reaction.  The 
d18:2 LCB-P was instead reactive, the substrate completely disappeared but we 
were not successful in detecting the DMDS modified species (Figure 6.4). 
Similarly the ozone reaction was not successful due to the Generation of highly 
unstable products. 
As shown in chapter 2, S. cerevisiae can incorporate the endogenous precursor 
palmitoleic acid (C16:1
Δ9cis
) and generate d18:1
Δ11
 LCB-P. This could also 
happen in mammals, which can incorporate palmitoleic acid (C16:1
Δ9cis
 is around 
~25% of palmitic acid in human plasma)
115
 into sphingolipids. The second double 
bond could be added at delta4 by the enzyme Des1 to generate d18:2
Δ4,11
 LCB-P 
(Figure 6.5a). Williams et al. used different fatty acyl-CoA thioesters (C12 to 
C24 and different unsaturations) to characterize the serine palmitoyltransferase 
(SPT) activity in synthesizing long-chain bases. Palmitoyl-CoA (C16:0) turned 
out to be the most preferred substrate. Palmitoleoyl-CoA (C16:1
Δ9cis
), the most 
common unsaturated fatty acid in mammals, was also shown to be a substrate,
190
 
even though with lower affinity.    




Figure 6.4. DMDS reaction on Human plasma LCB-P extract. LCB-P species from 
Human plasma were monitored before and after DMDS reaction, showing that only d18:2 
LCB-P was targeted.  
 
Figure 6.5. Stable Isotope labeled fatty acid supplementation (a) proposed 
biosynthetic pathway for d18:2 sphingolipids. (b) Experimental design and sphingolipid 
profiles in control and fatty acid labeled: ceramide (Extracted Ion chromatogram, 
analyzed in nanoESIchipQTOF, top panel) and LCB-P analysis (MRM chromatogram, 
analyzed in nanoESIQQQ, bottom panel). (c) MSMS spectra showing ceramides species. 
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To test if palmitoleic acid can be a precursor for the synthesis of d18:2, we 
supplemented the stable isotope labeled palmitoleic acid (
13
C16) (0.05% 
conjugated with fatty acid free BSA) in the culture media of Caco-2 cells and 
after 7 hours incubation we compared the LCB-P content of supplemented and 
control cells.  
Our findings showed that the sphingolipid levels were two fold lower in control 
cells when compared to fatty acid supplemented cells. LCB-P analysis showed the 
presence of both labeled d18:1
Δ11
 and also endogenous d18:1
Δ4
 in fatty acid 
supplemented cells. We managed to detect and quantify the endogenous d18:2 
LCB-P, but we could not detect or quantify the labeled d18:2 LCB-P (Figure 
6.5b, LCB-P MRM profile). Next, we checked if the labeled fatty acid was 
incorporated into ceramides by measuring the major endogenous ceramide species 
d18:1
Δ4
/C24:1 and labeled d18:1
Δ11
/24:1. These species co-elute in HPLCChip 
reverse phase mode, with the labeled one eluting slightly earlier. We were then 
able to detect the endogenous ceramide d18:2/24:1 and also the labeled 
d18:2
Δ4,11
/24:1 that were co-eluting at the same retention time (Figure 6.5b, 
Ceramide QTOF MS profiles). All the ceramide peaks were characterized by 
MSMS at high resolution. The MSMS spectra of ceramide (Figure 6.5c, MSMS 
spectra) d18:1
Δ4
/C24:1 (m/z 648) shows a clear sphingoid base fragment as base 
peak at m/z 264.26. However, the base peak for labeled ceramide 
d18:1
Δ11
/C24:1(m/z 664) was the dehydration (-H2O) product at m/z 646.67. This 
different fragmentation is due to the difference in the double bond position. Since 
we could measure the C16:1 incorporation into ceramides as d18:1
Δ11
/C24:1, we 
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tried to characterize the endogenous d18:1
Δ11
 ceramides in control cells. To 





 in Caco-2 cell extracts by UPLC, monitoring in MRM 
mode the water loss fragment unique for endogenous d18:1
Δ11
/C24:1 (Figure 
6.5d).  We thus reported for the first time the presence of different forms of d18:1 
in mammals. We then characterized the endogenous ceramide d18:2/C24:1 (m/z 
646), where the fragment at m/z 262.25 is the base peak. For the labeled ceramide 
d18:2
Δ4,11
/C24:1(m/z 662) we measured a similar fragmentation pattern except for 
a shift of +16m/z  due to the labeling. With these results we can support the 
hypothesis that the plamitoleic acid can be a precursor for de novo synthesis of 
sphingolipids, resulting in the presence of isobaric compounds containing d18:1 
LCBs. Thus it is very important to separate them by chromatography and use 
specific MRM transitions for quantification. Though we were able to detect the 
presence of d18:2
Δ4,11 
through labeling experiments, we cannot exclude the 
presence of the other natural isoforms d18:2
Δ4,14
, as claimed by other research 
groups.
  




plasma, even if 
the synthetic pathway and the physiological function of this molecule were never 
elucidated. Our analysis cannot be considered conclusive from an analytical point 
of view but suggests the existence of d18:2
Δ4,11 
LCB as an endogenous form. 
Further studies for a better structural characterization of this molecule are ongoing 
with the use of new techniques and the help of our collaborators. 
We can‘t exclude the influence of both genetic and environmental factors, as for 
example the dietary absorption of sphingolipids. Plants are a major producer of 





 (also called sphingadienes) that can be incorporated into 
glucosylceramides and absorbed by the intestinal cells of the mammals. As 
sphingadienes have shown cytotoxic effects on malignant colonic epithelial cell 
lines and intestinal tumorigenesis in a rodent model of colon cancer, there is a lot 
of interest around these molecules.
191-193
 For this reason, the confirmation of the 
existence of LCB-P d18:2 in mammals, and the ability to accurately quantify 
them by our method, will open new possibilities in the study of the anti-
carcinogenic properties of this class of molecules.  
 





7.0 Conclusions and future perspectives  
 
The goal of this research project was to develop novel technologies for the study 
of specific sphingolipids biology. Thanks to this new approach new lipid species 
were identified and quantified in biological samples and the novelty and the 
relevance of this work will now impact several aspects of the lipidomics research 
that are described here below.  
 Novel technology to drive better descriptive biochemistry  
Electrospray ionization mass spectrometry (MS) has become a 
proven technology for lipidomic analysis. Current approaches largely aim 
to obtain a comprehensive coverage of several lipid classes. We introduce 
a strategy for the capture of phospho-monoester lipids and improved 
detection and quantification of LCB-P. We achieved this via two main 
workflow improvements: (i) introduction of a new solid phase material for 
selective capture, thus enrichment, of phospho-monoester lipids based on 
the principle of molecularly imprinted polymers (MIPs). (ii) Optimized 
conditions for MS analysis of a particular class of bioactive lipids, namely 
‗sphingosine-1-phosphate‘ (S1P), often regarded to comprise one 
molecular entity alone. Our results demonstrate that, in addition to the 
known and described chemistry of S1P, there are many more, closely 
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related structural derivatives of S1P (LCB-P). We characterized several 
new LCB-Ps from different organisms and different tissues in this study. 
We term this approach 'deep profiling' as it revealed so far unknown 
chemical forms of LCB-P. This is a new concept of targeting specific 
classes of lipids via their enrichment and removal of unwanted material. 
The method is fast and easy to implement on existing analytical platforms.  
 Non imprinted polymers (NIP) vs Molecularly imprinted polymers (MIP) 
MIPs are obtained by polymerizing a mixture of cross-linkers and 
functional monomers in the presence of a template molecule. The 
imprinting effect is then a direct consequence of the presence of the 
template in the mixture. In the current research not much attention has 
been paid to NIPs as their binding properties are apparently difficult to 
predict. NIPs are non-specific binders of various classes of analytes, while 
MIPs should target molecules very specifically
150
. However this current 
view has been challenged by recently published papers
151
. The new 
hypothesis suggests that the presence of the template during MIP synthesis 
only acts to enhance binding properties that already exist in NIPs. The 
lack of high specificity of NIPs was turned to our advantage to target 
various classes of lipids containing phosphate monoesters with different 
chain lengths, unsaturations and other modifications like hydroxylations. 
After this first step we will now focus on the development of MIPs, to 
further improve the specificity for LCB-P based on fine molecular 
features. 
Conclusion and future perspectives 
101 
 
 Relevance in respect to known or not yet well described biochemical 
pathways 
The discovery of new LCB-Ps will trigger biological questions. 
For example, how are the new forms generated and degraded? S1P is a 
bottleneck metabolite, which links sphingolipids with other lipids. 
Irreversible cleavage of S1P by S1P lyase is a critical step that links 
sphingolipid metabolism with that of other lipids. The results from the 
lyase mutants demonstrate the unexpected accumulation of diverse LCB-
Ps when this single degradation step is impaired. It is known that chain 
length distributions are specific to certain tissues and dynamic during 
developmental stages. The metabolic regulation of S1P gradients is now 
regarded as a key characteristic of signaling mediated by this lipid. 
Discovery of new LCB-P derivatives therefore creates significantly new 
perspectives related to S1P signaling. 
 Protein-lipid interactions 
The realization that S1P is not a single chemical entity but may 
exert its actions as a family of lipid mediators with closely related 
structures, furthermore calls for more detailed characterization of S1P-
enzyme/receptor interactions and their molecular specificities (for 
example, since there are five receptors for S1P, there is not much evidence 
for endogenous ligands specificity despite the diversity of LCB-Ps), a 
foundation for biomolecular engineering and drug development. 
Therapeutic targeting of S1P receptors and metabolizing enzymes is 
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indeed a very active field of research.
194
 Fingolimod (a sphingosine-1-
receptor agonist) was approved for the treatment of multiple sclerosis in 
2010. And many other candidates are in development or clinical trials.
195
 
Our recently published work on the function of the Extended 
Synaptotagmin (E-Syt) as a membrane transporter of different lipid 
classes
59
, allowed us to develop an efficient methodology to study intact 
protein-lipid complexes by using mass spectrometry. The same approach 
will then be used to probe LCB-P interactions with specific protein 
binders. 
 
 Functional relevance  
  In human plasma d18:1 S1P  is the most abundant and the most 
studied LCB-P, due to its functional role in receptor binding, immune cell 
trafficking, cell proliferation and angiogenesis. However the functional 
role of the other LCB-Ps is still unknown. Humans have five different S1P 
receptors that theoretically could be specific for different molecular forms 
of LCB-P; by using synthetic pure LCB-Ps we will test their binding to 
different receptors
103
 and their biological effect.  
Not only the functional role of dienes-containing sphingolipids is 
unknown but also their synthetic pathway (mammals, fly); after detecting 
where dienes-containing LCB-Ps are present in different organisms, we 
are planning to perform a genetic analysis to find out which enzymes are 
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responsible for their synthesis and when they appeared on the evolutionary 
scale, to have more insights about the possible functions of dienes. 
   In yeast we identified for the first time unsaturated LCB-P species. 
As the specific desaturase is absent in S. cerevisiae we will try to clarify 
the synthetic mechanism of these molecules. Moreover specific molecular 
forms of LCB-Ps were found to be present in different amounts at 
different growth stages and they could regulate the cell cycle as previously 
suggested.
158, 159
 Our results are a demonstration of a highly dynamic 
nature of LCB-P metabolism as a function of cell physiology.  
  In D. melanogaster it‘s known that S1P lyase null mutants 
(Sply
05091
) accumulate LCB-Ps, showing abnormal flight muscles 
development and apoptosis in reproductive organs. Egg-laying is 
diminished in mutant females and spermatogenesis is defective in 
males
106
. From our results we found accumulation of many new species of 
LCB-P in these mutants and their role has now to be clarified. The 
discovery of d18 LCB-P especially supports the hypothesis of regulation 
of SREBP through this intermediate.
103
 The existence of this regulating 
molecule was always inferred but never measured in real samples before. 
Our discovery of phyto LCB-Ps in Drosophila also supports the idea of a 
dietary absorption of these species and opens the possibility to study their 
metabolism and influence on other lipid pathways.   
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 Novel Biomarkers 
Natural variations of S1P concentrations between the three major ethnic 
groups of Singapore showed significant differences between healthy 
Chinese, Indian and Malays. Although we cannot rule out life-style, 
environmental and dietary reasons for these observations we would like to 
put forward a hypothesis based on genetic variations of know metabolic 
pathways: does genetic variation in enzymes of fatty alcohol metabolism 
(fatty chain alcohols are key intermediates in S1P metabolism), and/or 
closely linked metabolic steps, lead to elevated levels of S1P? Alcohol 
dehydrogenases (ADH), enzymes generating substrates for aldehyde 
dehydrogenases (ALDH), show genetic variation between different ethnic 
groups and are less active in East Asians, such as the Chinese. This 
knowledge on natural variations could become a foundation for future 
studies on novel biomarkers in disease and clinical prognosis.  
In a recently initiated project, we started measuring the LCB-P species in 
plasma lipoproteins. The importance of measuring these molecules  in 
lipoproteins, especially in high density lipoproteins (HDL) , is related to 
their anti-atherogenic functions through S1P.
196
 Measuring the diversity of 
LCB-P in HDL will also help to understand their physiological functions 
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Appendix 2. Tandem MS of LCB-Ps in different organisms 
 
Appendix 2. Product ion analysis of derivatised LCB-Ps using collision induced 
dissociation (CID). Panel (a) shows S1P d18:1 for illustration purposes of the 
different fragments observed during tandem mass spectrometry. Fragments A and 
B are invariant and common to all LCB-P tested here. Fragment C is LCB-P 
species specific and recorded as the [M+HCOO]- adduct in negative mode (C**) . 
Panel (b) is a summary of the main fragments generated by CID fragmentation in 
both positive and negative mode for each LCB-P molecular species reported in 
this study. All data were collected using Quadrupole Time of Flight (QToF) mass 
spectrometry except # which were acquired on a triple quadrupole mass 
spectrometer.  
 












Long Chain Base  Phosphate 
(shown: S1P  d18:1) 
a 
b 
LCB - P 
  
Positive Ion Mode [M + ] 
  
  






p roduct  ions  (m/z) 




p roduct  ions  (m/z) 
  
A 







  C**   
  d14   
0 
  382.270   60.080   112.999   270.277   426.264   60. 056   110.984   366.208   
1 
  380.254   60.080   112.999   268.261   424.249   60.0 56   110.984   364.193   
2 
  378.238   60.080   112.999   266.247   422.235   60.057   110.984   362.178   
  d15   
0 
  396.284   60.080   112.998   284.292   440.279   60.057   110.984   380.222   
1 
  394.269   60.079   112.999   282.275   438.263   60.058   110.984   378.205   
2 
  392.255   60.080   nd   nd   nd   nd   nd   nd   
  d16   
0 
  410.301   60.083   112.999   298.309   454.294   60.058   110.984   394.236   
1 
  408.286   60.080   112.999   296.293   452.278   60.058   110.984   392.220   
2 
  406.270   60. 080   112.999   294.278   450.263   60.058   110.984   390.205   
  d17   
0 
  424.313   60.080   112.999   312.324   468.314   60.066   110.984   408.248   
1 
  422.299   60.080   112.999   310.308   466.297   60.059   110.984   406.238   
2 
  nd   nd   nd   nd   464.279   60.065   110.984   404.214   
  d18   
0 
  438.332   60 .08 4   112.999   326.321   482.32 4   60.0 62   110.984   422.262   
1 
  436.316   60.08 4   112.999   324.3 07   480.309   60.0 6 2   110.984   420.247   
13 
C 2 D 2 
  d18:1   440.33 4   60.080   112.999   328.3 2 5   484.33 0   60.02 0   110.984   424.31 0   
2 
  434.298   60.081   112.999   322.310   478.293   60.0 66   110.984   418.227   
  t18   0   454.321   60.079   112.998   342.331   498 .33 5   60.02 2   110.9 90   43 8 .313   
  d19   
0 
  452.342   60.080   112.999   340.282   496.342   60.040   111.009   436.371   
1 
  450.324   60.086   112.999   338.340   494.325   60.041   111.009   434.284   
  d20   
0 
  466.362   60 .079   112.999   354.368     nd   nd   nd   nd   
1 
  464.343   60.079   112.998   352.351   508.34 0   60.020   110.980   448.33 0   
  t20   
0 
  482.332   60.08 0   113.001   370.369   526.367   60.017   110.990   466.350   
1 
  480.336   60.079   112.998   368.348   524.3 
# 
  60.0 
# 
  110.9 
# 








Appnedix 3. MRM list for LCB-P measurements 
 
 
MRM LIST for LCB-P
Compound Group Compound Name Precursor Ion Product Ion
LCB-P t20:0 482.3 113
LCB-P t20:0 482.3 60.08
LCB-P t20:1 480.3 113
LCB-P t20:1 480.3 60.08
LCB-P d20:0 466.3 113
LCB-P d20:0 466.3 60.08
LCB-P d20:1 464.3 113
LCB-P d20:1 464.3 60.08
LCB-P d20:2 462.3 113
LCB-P d20:2 462.3 60.08
LCB-P d19:0 452.3 113
LCB-P d19:0 452.3 60.08
LCB-P d19:1 450.3 113
LCB-P d19:1 450.3 60.08
LCB-P d19:2 448.3 113
LCB-P d19:2 448.3 60.08
LCB-P t18:0 454.3 113
LCB-P t18:0 454.3 60.08
LCB-P t18:1 452.3 113
LCB-P t18:1 452.3 60.08
13
C2D2-S1P d18:1 440.3 113
13
C2D2-S1P d18:1 440.3 60.08
SA1P d18:0 438.3 113
SA1P d18:0 438.3 60.08
S1P d18:1 436.3 113
S1P d18:1 436.3 60.08
LCB-P d18:2 434.3 113
LCB-P d18:2 434.3 60.08
LCB-P d17:0 424.3 113
LCB-P d17:0 424.3 60.08
LCB-P d17:1 422.3 113
LCB-P d17:1 422.3 60.08
LCB-P d17:2 420.3 113
LCB-P d17:2 420.3 60.08
LCB-P d16:0 410.3 113
LCB-P d16:0 410.3 60.08
LCB-P d16:1 408.3 113
LCB-P d16:1 408.3 60.08
LCB-P d16:2 406.3 113
LCB-P d16:2 406.3 60.08
LCB-P d15:0 396.2 113
LCB-P d15:0 396.2 60.08
LCB-P d15:1 394.2 113
LCB-P d15:1 394.2 60.08
LCB-P d15:2 392.2 113
LCB-P d15:2 392.2 60.08
LCB-P d14:0 382.3 113
LCB-P d14:0 382.3 60.08
LCB-P d14:1 380.3 113
LCB-P d14:1 380.3 60.08
LCB-P d14:2 378.2 113
LCB-P d14:2 378.2 60.08
LCB-P d12:0 354.2 113
LCB-P d12:0 354.2 60.08
LCB-P d12:1 352.2 113
LCB-P d12:1 352.2 60.08
LCB-P d12:2 350.2 113




Cell Accelerator Voltage 7
Polarity Positive
Quantification: peak area of the sample was compared to peak area of Internal Standard ISTD for quantification
d12













Appendix 4. LOD measurements 
 
 
Appendix 4. Estimation of the limit of detection (LOD) based on signal to 
noise ratio (S/N) in plasma before (panel a) and after (panel b) IMP enrichment. 
Shown are extracted MRM peaks (440.3/60.08, i.e. derivatized 
13
C2D2 S1P) of 0.3 
fmol 
13








Intensity Counts vs. Acquisition Time (min)



























Intensity Counts vs. Acquisition Time (min)
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a. Sphingolipids MRM list 
 
Dynamic MRM
Compound Group Compound Name Precursor Ion MS1 Res Product Ion MS2 Res Ret Time (min) Delta Ret Time Fragmentor Collision Energy Cell Accelerator Voltage Polarity
d14:0/22:0 568.6 Unit 210.21 Unit 6.19 0.88 135 30 7 Positive
d14:0/20:0 540.6 Unit 210.21 Unit 5.82 0.58 135 30 7 Positive
d14:1/26:1 620.6 Unit 208.2 Unit 6.48 0.65 135 30 7 Positive
d14:1/24:1 592.6 Unit 208.2 Unit 6.19 0.88 135 30 7 Positive
d14:1/24:0 594.6 Unit 208.2 Unit 6.51 1.1 135 30 7 Positive
d14:1/22:1 564.6 Unit 208.2 Unit 5.82 1.27 135 30 7 Positive
d14:1/22:0 566.6 Unit 208.2 Unit 6.19 0.88 135 30 7 Positive
d14:1/20:1 536.6 Unit 208.2 Unit 5.46 1.43 135 30 7 Positive
d14:1/20:0 538.6 Unit 208.2 Unit 5.82 1.07 135 30 7 Positive
d14:1/18:1 508.6 Unit 208.2 Unit 4.36 0.54 135 30 7 Positive
d14:1/18:0 510.6 Unit 208.2 Unit 5.42 0.86 135 30 7 Positive
d14:1/16:1 480.6 Unit 208.2 Unit 3.19 0.55 135 30 7 Positive
d14:1/16:0 482.6 Unit 208.2 Unit 3.19 0.44 135 30 7 Positive
d14:1/14:0 454.6 Unit 208.2 Unit 4.58 0.46 135 30 7 Positive
(GluCer)d14:1/24:1 754.7 Unit 208.2 Unit 4.5 1.21 135 35 7 Positive
(GluCer)d14:1/24:0 756.7 Unit 208.2 Unit 7.23 0.72 135 35 7 Positive
(GluCer)d14:1/22:0 728.7 Unit 208.2 Unit 5.8 0.75 135 35 7 Positive
(GluCer)d14:1/20:1 698.7 Unit 208.2 Unit 5.32 0.69 135 35 7 Positive
(GluCer)d14:1/20:0 700.7 Unit 208.2 Unit 5.44 0.84 135 35 7 Positive
(GluCer)d14:1/18:0 672.7 Unit 208.2 Unit 5.04 0.77 135 35 7 Positive
(OH-GluCer)d14:1/24:1 770.7 Unit 208.2 Unit 5.69 0.57 135 35 7 Positive
(OH-GluCer)d14:1/24:0 772.7 Unit 208.2 Unit 6.75 0.95 135 35 7 Positive
(OH-GluCer)d14:1/22:0 744.7 Unit 208.2 Unit 5.69 0.99 135 35 7 Positive
(OH-GluCer)d14:1/20:0 716.7 Unit 208.2 Unit 5.33 0.77 135 35 7 Positive
(OH-GluCer)d14:1/18:0 688.7 Unit 208.2 Unit 4.93 0.99 135 35 7 Positive
d14:1/24:0(OH) 610.6 Unit 208.2 Unit 6.18 0.77 135 30 7 Positive
d14:1/22:1(OH) 580.6 Unit 208.2 Unit 6.33 0.88 135 30 7 Positive
d14:1/22:0(OH) 582.6 Unit 208.2 Unit 5.86 1.32 135 30 7 Positive
d14:1/20:1(OH) 552.6 Unit 208.2 Unit 5.93 0.77 135 30 7 Positive
d14:1/20:0(OH) 554.6 Unit 208.2 Unit 5.6 0.7 135 30 7 Positive
d14:1/18:1(OH) 524.5 Unit 208.2 Unit 5.61 0.56 135 30 7 Positive
(PECer)d14:1/26:0 745.6 Unit 208.2 Unit 6.72 2 135 40 7 Positive
(PE-Cer)d14:1/25:0 731.6 Unit 208.2 Unit 5.29 0.53 135 40 7 Positive
(PE-Cer)d14:1/24:0 717.6 Unit 208.2 Unit 5.33 0.59 135 40 7 Positive
(PE-Cer)d14:1/23:0 703.5 Unit 208.2 Unit 4.3 1.07 135 40 7 Positive
(PE-Cer)d14:1/22:1 687.6 Unit 208.2 Unit 5 2 135 40 7 Positive
(PE-Cer)d14:1/22:0 689.6 Unit 208.2 Unit 5.7 0.66 135 40 7 Positive
(PE-Cer)d14:1/20:0 661.6 Unit 208.2 Unit 5.33 0.77 135 40 7 Positive
(PE-Cer)d14:1/18:1 631.6 Unit 208.2 Unit 5.11 2 135 40 7 Positive
(PE-Cer)d14:1/18:0 633.6 Unit 208.2 Unit 4.93 0.55 135 40 7 Positive
(OH-PECer)d14:1/24:1 731.6 Unit 208.2 Unit 5.29 0.53 135 40 7 Positive
(OH-PECer)d14:1/24:1 731.6 Unit 208.2 Unit 5.29 0.53 135 40 7 Positive
(OH-PECer)d14:1/22:1 703.6 Unit 208.2 Unit 4.3 1.07 135 40 7 Positive
(OH-PECer)d14:1/22:0 705.6 Unit 208.2 Unit 4.3 0.66 135 40 7 Positive
d14:2/26:1 600.6 Unit 206.19 Unit 6.36 0.64 135 30 7 Positive
d14:2/24:1 572.6 Unit 206.19 Unit 6.04 0.73 135 30 7 Positive
d14:2/24:0 574.6 Unit 206.19 Unit 6.37 1.1 135 30 7 Positive
d14:2/22:1 544.6 Unit 206.19 Unit 5.71 1.1 135 30 7 Positive
d14:2/22:0 546.6 Unit 206.19 Unit 6.01 1.09 135 30 7 Positive
d14:2/20:1 516.6 Unit 206.19 Unit 5.42 1.32 135 30 7 Positive
d14:2/20:0 518.6 Unit 206.19 Unit 5.64 1.1 135 30 7 Positive
d14:2/18:0 490.6 Unit 206.19 Unit 5.24 0.66 135 30 7 Positive
d14:2/16:0 462.6 Unit 206.19 Unit 4.84 0.88 135 30 7 Positive
d14:2/14:0 434.6 Unit 206.19 Unit 4.42 1.01 135 30 7 Positive
(GluCer)d14:2/24:0 736.7 Unit 206.19 Unit 6 0.6 135 35 7 Positive
(GluCer)d14:2/22:0 708.7 Unit 206.19 Unit 5.66 0.99 135 35 7 Positive
(GluCer)d14:2/20:0 680.7 Unit 206.19 Unit 5.26 0.77 135 35 7 Positive
(GluCer)d14:2/18:0 652.7 Unit 206.19 Unit 4.86 0.66 135 35 7 Positive
(GluCer)d14:2/16:0 624.7 Unit 206.19 Unit 6.24 1.29 135 35 7 Positive
(OH-GluCer)d14:2/24:0 754.7 Unit 206.19 Unit 4.9 0.72 135 35 7 Positive
(OH-GluCer)d14:2/22:0 724.7 Unit 206.19 Unit 5.54 0.87 135 35 7 Positive
(OH-GluCer)d14:2/20:0 696.7 Unit 206.19 Unit 5.15 0.55 135 35 7 Positive
(OH-GluCer)d14:2/18:0 668.7 Unit 206.19 Unit 4.75 0.55 135 35 7 Positive
d14:2/24:0(OH) 590.6 Unit 206.19 Unit 6.19 0.66 135 30 7 Positive
d14:2/22:1(OH) 560.6 Unit 206.19 Unit 6.12 0.61 135 30 7 Positive
d14:2/22:0(OH) 562.6 Unit 206.19 Unit 5.82 0.99 135 30 7 Positive
d14:2/20:1(OH) 532.6 Unit 206.19 Unit 5.86 0.99 135 30 7 Positive
d14:2/20:0(OH) 534.6 Unit 206.19 Unit 5.46 0.77 135 30 7 Positive
d14:2/18:1(OH) 504.6 Unit 206.19 Unit 5.46 0.55 135 30 7 Positive
d14:2/18:0(OH) 506.6 Unit 206.19 Unit 5.06 0.88 135 30 7 Positive
d14:2/16:1(OH) 476.6 Unit 206.19 Unit 3.73 0.97 135 30 7 Positive
(PECer)d14:2/26:0 743.6 Unit 206.19 Unit 6.6 2 135 40 7 Positive
(PE-Cer)d14:2/23:0 701.5 Unit 206.19 Unit 4.78 0.5 135 40 7 Positive
(PECer)d14:2/22:0 687.6 Unit 206.19 Unit 5.55 0.77 135 40 7 Positive
(PE-Cer)d14:2/21:0 673.5 Unit 206.19 Unit 4.38 0.44 135 40 7 Positive
(PECer)d14:2/20:0 659.6 Unit 206.19 Unit 5.15 0.66 135 40 7 Positive
(PE-Cer)d14:2/18:1 629.6 Unit 206.19 Unit 5.1 2 135 40 7 Positive
(PECer)d14:2/18:0 631.6 Unit 206.19 Unit 4.75 0.66 135 40 7 Positive
(PECer)d14:2/16:0 603.6 Unit 206.19 Unit 4.35 1.14 135 40 7 Positive
(OH-PECer)d14:2/24:1 713.7 Unit 206.19 Unit 6.63 1 135 40 7 Positive
(OH-PECer)d14:2/22:1 701.6 Unit 206.19 Unit 4.78 0.5 135 40 7 Positive
(OH-PECer)d14:2/22:0 703.6 Unit 206.19 Unit 4.3 0.44 135 40 7 Positive
(OH-PECer)d14:2/20:1 673.7 Unit 206.19 Unit 4.38 0.44 135 40 7 Positive


















a. Sphingolipids MRM list continued… 
 
d16:0/d16:1 510.6 Unit 238.24 Unit 4.36 1.03 135 30 7
d16:0/d16:0 512.6 Unit 238.24 Unit 4.3 0.6 135 30 7
d16:0/20:0 568.6 Unit 238.24 Unit 6.1 2 135 30 7
(PECer)d16:0/22:2 715.7 Unit 238.24 Unit 5.14 0.64 135 40 7
(PECer)d16:0/22:1 717.7 Unit 238.24 Unit 5.44 0.83 135 40 7
(PECer)d16:0/20:1 689.6 Unit 238.24 Unit 5.07 1.21 135 40 7
(PECer)d16:0/20:0 691.6 Unit 238.24 Unit 5.37 0.77 135 40 7
(PECer)d16:0/18:0 663.6 Unit 238.24 Unit 5 0.5 135 40 7
d16:1/24:0 622.6 Unit 236.23 Unit 6.77 0.68 135 30 7
d16:1/22:1 592.6 Unit 236.23 Unit 6.13 0.61 135 30 7
d16:1/22:0 594.6 Unit 236.23 Unit 6.44 0.88 135 30 7
d16:1/20:1 564.6 Unit 236.23 Unit 5.79 1.38 135 30 7
d16:1/20:0 566.6 Unit 236.23 Unit 6.15 0.88 135 30 7
d16:1/18:0 538.6 Unit 236.23 Unit 5.79 0.66 135 30 7
d16:1/16:1 508.6 Unit 236.23 Unit 4.32 0.77 135 30 7
d16:1/16:0 510.6 Unit 236.23 Unit 4.3 0.6 135 30 7
(GluCer)d16:1/22:0 756.7 Unit 236.23 Unit 6.09 0.61 135 35 7
(GluCer)d16:1/20:1 726.7 Unit 236.23 Unit 4.8 0.8 135 35 7
(GluCer)d16:1/20:0 728.7 Unit 236.23 Unit 5.76 0.77 135 35 7
(GluCer)d16:1/18:0 700.7 Unit 236.23 Unit 5.4 0.69 135 35 7
(OH-GluCer)d16:1/20:1 742.7 Unit 236.23 Unit 6.84 1.12 135 35 7
(OH-GluCer)d16:1/20:0 744.7 Unit 236.23 Unit 6.84 1.12 135 35 7
(OH-GluCer)d16:1/16:0 688.7 Unit 236.23 Unit 5.06 1.38 135 35 7
d16:1/24:0(OH) 638.6 Unit 236.23 Unit 5.9 1.5 135 30 7
d16:1/22:0(OH) 610.6 Unit 236.23 Unit 6.13 0.62 135 30 7
d16:1/20:0(OH) 582.6 Unit 236.23 Unit 4.78 0.95 135 30 7
d16:1/18:1(OH) 552.6 Unit 236.23 Unit 5.93 0.77 135 30 7
(PE-Cer)d16:1/22:1 715.6 Unit 236.23 Unit 5.43 1.03 135 40 7
(PE-Cer)d16:1/22:0 717.6 Unit 236.23 Unit 5.43 1.08 135 40 7
(PE-Cer)d16:1/20:0 689.6 Unit 236.23 Unit 5.06 1 135 40 7
d16:1PEcer-OH (OH-PECer)d16:1/22:1 731.6 Unit 236.23 Unit 6.6 1 135 40 7
d16:2/24:1 600.6 Unit 234.22 Unit 6.3 0.8 135 30 7
d16:2/24:0 602.6 Unit 234.22 Unit 6.62 0.66 135 30 7
d16:2/22:1 572.6 Unit 234.22 Unit 6.15 0.62 135 30 7
d16:2/22:0 574.6 Unit 234.22 Unit 6.33 0.88 135 30 7
d16:2/20:1 544.6 Unit 234.22 Unit 5.79 0.58 135 30 7
d16:2/20:0 546.6 Unit 234.22 Unit 5.97 0.86 135 30 7
d16:2/18:1 516.6 Unit 234.22 Unit 5.6 0.7 135 30 7
d16:2/18:0 518.6 Unit 234.22 Unit 5.61 1.29 135 30 7
d16:2/14:0 462.6 Unit 234.22 Unit 4.79 0.77 135 30 7
(GluCer)d16:2/22:0 736.7 Unit 234.22 Unit 5.98 0.6 135 35 7
(GluCer)d16:2/20:0 708.7 Unit 234.22 Unit 5.62 0.56 135 35 7
(GluCer)d16:2/18:0 680.7 Unit 234.22 Unit 5.23 0.76 135 35 7
(OH-GluCer)d16:2/22:0 752.7 Unit 234.22 Unit 5.86 0.85 135 35 7
(OH-GluCer)d16:2/20:0 724.7 Unit 234.22 Unit 5.47 0.57 135 35 7
(OH-GluCer)d16:2/18:0 696.7 Unit 234.22 Unit 5.07 0.51 135 35 7
d16:2/24:0(OH) 618.5 Unit 234.22 Unit 4.13 0.41 135 30 7
d16:2/22:0(OH) 590.6 Unit 234.22 Unit 6.19 0.62 135 30 7
d16:2/20:0(OH) 562.4 Unit 234.22 Unit 5.79 0.88 135 30 7
d16:2/18:1(OH) 532.4 Unit 234.22 Unit 5.94 0.59 135 30 7
d16:2/18:0(OH) 534.6 Unit 234.22 Unit 5.42 0.55 135 30 7
(PECer)d16:2/22:1 713.6 Unit 234.22 Unit 4.2 0.52 135 40 7
(PECer)d16:2/20:0 687.6 Unit 234.22 Unit 5.51 1.5 135 40 7
(PECer)d16:2/18:0 659.6 Unit 234.22 Unit 5.12 0.65 135 40 7
(OH-PECer)d16:2/24:0 759.6 Unit 234.22 Unit 5.71 1.5 135 40 7
(OH-PECer)d16:2/20:0 703.6 Unit 234.22 Unit 6.4 0.66 135 40 7
d18:0/18:0 568.6 Unit 266.27 Unit 6.1 2 135 30 7
d18:0/16:1 538.6 Unit 266.27 Unit 6 0.85 135 30 7
d18:0Glucer (GluCer)d18:0/16:0 702.6 Unit 266.27 Unit 4.27 0.66 135 35 7
(PECer)d18:0/22:2 743.7 Unit 266.27 Unit 5.5 0.55 135 40 7
(PECer)d18:0/22:1 745.7 Unit 266.27 Unit 5.76 1.43 135 40 7
(PECer)d18:0/22:0 747.7 Unit 266.27 Unit 5.76 0.88 135 40 7
(PECer)d18:0/20:1 717.7 Unit 266.27 Unit 5.44 1.32 135 40 7
(PECer)d18:0/20:0 719.7 Unit 266.27 Unit 5.73 0.77 135 40 7
(PECer)d18:0/18:0 691.7 Unit 266.27 Unit 5.37 0.54 135 40 7
d18:1/C8:0_STD 588.6 Unit 264.26 Unit 3.91 1.32 135 35 7
d18:1/C17:0_STD 552.6 Unit 264.26 Unit 5.93 1.31 135 30 7
d18:1/22:0(OH) 638.6 Unit 264.26 Unit 5.9 1.5 135 30 7
d18:1/22:0 622.6 Unit 264.26 Unit 6.73 1.12 135 30 7
d18:1/20:0 594.6 Unit 264.26 Unit 6.45 1.12 135 30 7
d18:1/18:1 564.6 Unit 264.26 Unit 5.6 0.94 135 30 7
d18:1/18:0 566.6 Unit 264.26 Unit 6.11 1.2 135 30 7
d18:1/16:1 536.6 Unit 264.26 Unit 5.94 0.66 135 30 7
d18:1/16:0 538.6 Unit 264.26 Unit 5.75 0.58 135 30 7
d18:1-OH d18:1/18:1(OH) 580.6 Unit 264.26 Unit 6.33 0.63 135 30 7
d18:2/20:0(OH) 590.6 Unit 262.25 Unit 6.19 0.62 135 30 7
d18:2/18:1 544.6 Unit 262.25 Unit 5.5 1.5 135 30 7
d18:2/16:1 516.6 Unit 262.25 Unit 5.6 1.5 135 30 7






















b. Sphingolipid quantitation in wild type and Sply mutants 
 
wt_-_r1.d wt_-_r2.d wt_-_r3.d Mean SD sply-sply_-_r1.dsply-sply_-_r2.dsply-sply_-_r3.d Mean SD wt_+_r1.d wt_+_r2.d wt_+_r3.d Mean SD sply-sply_+_r1.dsply-sply_+_r2.dsply-sply_+_r3.dMean SD
(GluCer)d14:1/18:0 2.4 2.0 1.6 2.0 0.4 1.1 0.8 1.3 1.0 0.2 0.4 0.4 0.3 0.4 0.1 1.0 3.4 3.2 2.5 1.4
(GluCer)d14:1/20:0 6.6 5.4 4.7 5.5 1.0 5.8 4.2 5.3 5.1 0.8 1.6 1.5 1.2 1.4 0.2 3.4 7.1 6.7 5.7 2.1
(GluCer)d14:1/20:1 0.4 0.2 0.3 0.3 0.1 0.5 0.3 0.4 0.4 0.1 0.1 0.1 0.1 0.1 0.0 0.2 0.4 0.3 0.3 0.1
(GluCer)d14:1/22:0 5.3 4.1 3.4 4.3 0.9 4.5 3.4 4.1 4.0 0.5 1.2 1.1 1.0 1.1 0.1 2.2 5.0 4.8 4.0 1.5
(GluCer)d14:1/24:0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0
(GluCer)d14:1/24:1 0.3 0.2 0.2 0.2 0.0 0.5 0.3 0.4 0.4 0.1 0.1 0.1 0.1 0.1 0.0 0.0 0.2 0.2 0.1 0.1
(GluCer)d14:2/16:0 0.1 0.0 0.0 0.1 0.0 0.2 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.0
(GluCer)d14:2/18:0 0.8 0.6 0.6 0.7 0.1 0.6 0.3 0.6 0.5 0.1 0.2 0.2 0.2 0.2 0.0 0.3 1.9 1.6 1.3 0.9
(GluCer)d14:2/20:0 2.8 2.1 2.2 2.4 0.4 3.0 1.9 2.4 2.5 0.5 1.1 1.0 0.9 1.0 0.1 2.0 4.1 3.5 3.2 1.1
(GluCer)d14:2/22:0 1.8 1.2 1.3 1.4 0.3 1.8 1.2 1.5 1.5 0.3 0.8 0.8 0.6 0.7 0.1 1.2 2.3 2.0 1.8 0.6
(GluCer)d14:2/24:0 0.5 0.4 0.4 0.4 0.1 0.4 0.3 0.4 0.4 0.1 0.3 0.3 0.2 0.2 0.0 0.3 0.5 0.5 0.4 0.1
(GluCer)d16:1/18:0 0.1 0.1 0.1 0.1 0.0 0.2 0.1 0.2 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.6 0.5 0.4 0.2
(GluCer)d16:1/20:0 0.8 0.5 0.5 0.6 0.2 1.3 0.9 1.0 1.1 0.2 0.2 0.3 0.2 0.3 0.0 0.9 1.5 1.7 1.4 0.4
(GluCer)d16:1/22:0 1.0 1.0 0.8 0.9 0.1 1.1 0.7 1.0 0.9 0.2 0.4 0.4 0.4 0.4 0.0 0.7 1.3 1.6 1.2 0.5
(GluCer)d16:2/18:0 0.2 0.1 0.2 0.2 0.1 0.8 0.7 0.9 0.8 0.1 0.1 0.1 0.1 0.1 0.0 0.7 2.9 2.4 2.0 1.1
(GluCer)d16:2/20:0 1.0 0.6 0.7 0.8 0.2 4.5 3.9 3.9 4.1 0.3 0.7 0.7 0.7 0.7 0.0 4.1 9.6 8.4 7.4 2.9
(GluCer)d16:2/22:0 0.9 0.8 0.7 0.8 0.1 4.2 4.2 4.6 4.3 0.2 0.6 0.6 0.6 0.6 0.0 3.4 8.8 7.0 6.4 2.8
(OH-GluCer)d14:1/18:0 0.4 0.4 0.3 0.4 0.1 0.3 0.2 0.4 0.3 0.1 0.3 0.2 0.2 0.2 0.0 0.2 0.5 0.4 0.3 0.1
(OH-GluCer)d14:1/20:0 4.5 3.1 3.1 3.6 0.8 5.1 3.5 4.5 4.4 0.8 1.6 1.4 1.3 1.4 0.1 2.6 4.3 3.1 3.3 0.9
(OH-GluCer)d14:1/22:0 1.2 0.8 0.9 1.0 0.2 1.5 1.0 1.1 1.2 0.3 0.3 0.2 0.2 0.3 0.1 0.6 0.9 0.6 0.7 0.1
(OH-GluCer)d14:1/24:1 0.2 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.0
(OH-GluCer)d14:2/18:0 0.3 0.2 0.2 0.3 0.1 0.2 0.1 0.1 0.1 0.0 0.2 0.1 0.1 0.1 0.0 0.1 0.3 0.3 0.2 0.1
(OH-GluCer)d14:2/20:0 3.3 2.2 2.4 2.6 0.6 4.1 2.3 2.9 3.1 0.9 1.4 1.2 1.1 1.2 0.1 1.9 4.3 4.8 3.7 1.6
(OH-GluCer)d14:2/22:0 1.4 0.9 1.0 1.1 0.3 2.6 1.5 1.8 2.0 0.6 0.6 0.6 0.6 0.6 0.0 1.1 2.1 2.4 1.9 0.7
(OH-GluCer)d14:2/24:0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
(OH-GluCer)d16:1/16:0 0.1 0.0 0.1 0.1 0.0 0.1 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0
(OH-GluCer)d16:1/20:0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0
(OH-GluCer)d16:2/18:0 0.6 0.5 0.5 0.5 0.1 0.2 0.1 0.1 0.1 0.0 0.2 0.2 0.2 0.2 0.0 0.2 0.3 0.3 0.3 0.1
(OH-GluCer)d16:2/20:0 1.6 1.5 1.3 1.5 0.2 1.7 1.2 1.3 1.4 0.3 1.2 1.1 0.9 1.1 0.1 1.2 2.7 2.2 2.0 0.8
(OH-GluCer)d16:2/22:0 1.1 0.9 0.8 0.9 0.1 1.8 1.4 1.4 1.5 0.2 1.2 1.1 1.1 1.1 0.1 1.4 1.8 1.4 1.5 0.2
(OH-PECer)d14:1/22:1 0.2 0.1 0.1 0.1 0.0 0.2 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.0 0.0 0.1 0.1 0.1 0.0
(OH-PECer)d14:1/24:1 0.1 0.1 0.1 0.1 0.0 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.0
(OH-PECer)d14:2/20:0 3.2 2.1 2.5 2.6 0.6 2.0 1.8 2.3 2.0 0.3 2.1 1.9 1.8 1.9 0.2 2.2 3.1 2.4 2.6 0.5
(OH-PECer)d16:2/24:0 0.1 0.1 0.2 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0
(PE-Cer)d14:1/18:0 2.2 1.8 1.7 1.9 0.3 1.9 1.3 2.0 1.8 0.4 0.7 0.6 0.6 0.6 0.0 1.0 1.9 1.6 1.5 0.5
(PE-Cer)d14:1/20:0 9.1 7.1 6.8 7.7 1.3 7.1 5.3 6.1 6.2 0.9 3.3 3.3 2.9 3.2 0.3 5.1 5.8 5.0 5.3 0.4
(PE-Cer)d14:1/22:0 13.2 9.0 9.9 10.7 2.2 10.3 7.5 9.0 8.9 1.4 5.3 5.2 4.6 5.0 0.4 5.9 7.6 6.9 6.8 0.9
(PE-Cer)d14:1/22:1 0.2 0.2 0.2 0.2 0.0 0.2 0.2 0.2 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
(PE-Cer)d14:1/23:0 0.2 0.1 0.1 0.1 0.0 0.2 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.0 0.0 0.1 0.1 0.1 0.0
(PE-Cer)d14:1/24:0 0.7 0.5 0.6 0.6 0.1 0.8 0.6 0.8 0.7 0.1 0.2 0.3 0.2 0.2 0.0 0.4 0.7 0.5 0.5 0.2
(PE-Cer)d14:1/25:0 0.1 0.1 0.1 0.1 0.0 0.1 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0
(PECer)d14:1/26:0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
(PECer)d14:2/16:0 0.3 0.2 0.2 0.2 0.0 0.1 0.1 0.1 0.1 0.0 0.2 0.2 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.0
(PECer)d14:2/18:0 3.4 2.3 2.6 2.8 0.6 2.4 1.7 2.6 2.3 0.5 2.4 2.1 1.8 2.1 0.3 1.4 2.8 2.7 2.3 0.8
(PE-Cer)d14:2/18:1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
(PECer)d14:2/20:0 19.9 14.1 15.9 16.6 3.0 20.6 16.6 22.0 19.7 2.8 14.1 13.5 12.4 13.3 0.9 16.8 23.4 16.6 18.9 3.9
(PECer)d14:2/22:0 17.7 12.4 13.8 14.7 2.8 18.1 13.9 17.8 16.6 2.3 13.0 12.4 11.8 12.4 0.6 15.4 20.5 14.2 16.7 3.4
(PE-Cer)d14:2/23:0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
(PECer)d16:0/18:0 0.2 0.2 0.2 0.2 0.0 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.0
(PECer)d16:0/20:0 0.8 0.6 0.6 0.7 0.1 1.0 0.7 0.8 0.8 0.2 0.3 0.3 0.4 0.3 0.0 0.4 0.7 0.7 0.6 0.2
(PECer)d16:0/20:1 2.0 1.3 1.4 1.6 0.3 1.9 1.5 1.6 1.7 0.2 1.2 1.2 1.0 1.1 0.1 0.7 1.1 1.1 1.0 0.2
(PECer)d16:0/22:1 1.4 0.9 1.0 1.1 0.3 1.6 1.2 1.2 1.3 0.2 0.9 0.8 0.7 0.8 0.1 0.5 0.9 0.9 0.8 0.2
(PECer)d16:0/22:2 0.3 0.2 0.2 0.2 0.1 0.2 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.0 0.2 0.1 0.1 0.1 0.1
(PE-Cer)d16:1/20:0 0.5 0.4 0.4 0.4 0.0 0.9 0.5 0.6 0.7 0.2 0.3 0.3 0.3 0.3 0.0 0.7 0.5 0.6 0.6 0.1
(PE-Cer)d16:1/22:0 1.1 0.8 0.9 0.9 0.2 1.0 0.9 1.0 1.0 0.1 0.5 0.7 0.5 0.6 0.1 0.8 0.9 0.9 0.9 0.0
(PE-Cer)d16:1/22:1 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
(PECer)d16:2/18:0 0.6 0.4 0.6 0.5 0.1 1.4 1.0 1.6 1.4 0.3 0.4 0.5 0.6 0.5 0.1 0.9 1.6 1.4 1.3 0.4
(PECer)d16:2/20:0 1.5 1.3 1.6 1.5 0.1 6.0 5.1 6.2 5.8 0.6 1.4 1.6 1.7 1.6 0.1 4.8 6.6 5.5 5.6 0.9
(PECer)d18:0/18:0 0.1 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0
(PECer)d18:0/20:0 1.6 1.1 1.1 1.2 0.3 1.3 0.8 1.1 1.1 0.2 0.6 0.6 0.5 0.6 0.1 0.5 0.9 0.9 0.8 0.2
(PECer)d18:0/20:1 1.5 1.0 1.2 1.2 0.2 1.6 1.1 1.3 1.4 0.3 0.9 0.8 0.8 0.9 0.0 0.6 1.0 0.9 0.8 0.2
(PECer)d18:0/22:0 0.4 0.3 0.3 0.3 0.1 0.3 0.2 0.3 0.3 0.0 0.2 0.2 0.2 0.2 0.0 0.2 0.3 0.2 0.2 0.0
(PECer)d18:0/22:1 3.2 2.1 2.4 2.5 0.6 3.6 2.7 3.1 3.2 0.4 1.9 1.9 1.6 1.8 0.1 1.6 2.4 2.2 2.1 0.4
(PECer)d18:0/22:2 0.5 0.3 0.3 0.4 0.1 0.2 0.2 0.2 0.2 0.0 0.2 0.2 0.1 0.2 0.0 0.3 0.2 0.2 0.2 0.1
d14:0/20:0 0.4 0.3 0.3 0.3 0.1 0.5 0.4 0.5 0.4 0.1 0.1 0.1 0.1 0.1 0.0 0.3 0.5 0.5 0.4 0.1
d14:0/22:0 0.6 0.6 0.5 0.5 0.1 0.5 0.4 0.6 0.5 0.1 0.2 0.2 0.2 0.2 0.0 0.4 0.8 0.6 0.6 0.2
d14:1/14:0 0.1 0.1 0.1 0.1 0.0 0.2 0.2 0.9 0.4 0.4 0.1 0.1 0.1 0.1 0.0 0.3 0.6 1.3 0.7 0.5
d14:1/18:0 1.0 1.0 0.8 0.9 0.1 0.9 0.6 0.9 0.8 0.2 0.3 0.3 0.2 0.3 0.0 0.6 1.2 1.0 0.9 0.3
d14:1/20:0 21.3 20.7 16.9 19.7 2.4 16.4 11.4 14.5 14.1 2.5 7.7 7.4 6.2 7.1 0.8 14.1 15.5 14.8 14.8 0.7
d14:1/20:1 0.1 0.1 0.1 0.1 0.0 0.1 0.0 0.1 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.0
d14:1/22:1 0.7 0.8 0.7 0.7 0.0 1.2 0.9 1.0 1.0 0.2 0.3 0.3 0.2 0.2 0.0 0.3 0.3 0.6 0.4 0.1
d14:1/24:1 3.2 2.7 2.6 2.8 0.3 4.4 3.6 4.3 4.1 0.4 0.9 0.9 0.7 0.8 0.1 0.9 1.0 1.3 1.1 0.3
d14:1/26:1 0.5 0.4 0.4 0.4 0.1 0.4 0.3 0.4 0.4 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0
d14:2/14:0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.0
d14:2/16:0 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.3 0.2 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.2 0.2 0.2 0.1
d14:2/18:0 0.6 0.5 0.4 0.5 0.1 0.6 0.3 0.5 0.5 0.1 0.3 0.3 0.2 0.3 0.0 0.3 0.7 0.7 0.6 0.3
d14:2/20:0 3.5 2.6 2.7 3.0 0.5 5.4 3.7 4.8 4.6 0.9 2.4 2.3 2.0 2.2 0.2 4.1 5.7 4.7 4.8 0.8
d14:2/20:1 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.1 0.1 0.1 0.0
d14:2/22:0 11.8 9.4 8.6 9.9 1.7 12.3 10.8 13.5 12.2 1.3 8.2 8.2 7.3 7.9 0.5 11.4 16.9 12.6 13.6 2.9
d14:2/22:1 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.0 0.2 0.2 0.2 0.2 0.0
d14:2/24:0 2.0 1.6 1.5 1.7 0.3 2.0 1.6 2.0 1.8 0.2 1.2 1.3 1.2 1.2 0.1 1.8 2.1 1.5 1.8 0.3
d14:2/24:1 0.8 0.6 0.6 0.6 0.1 1.2 0.9 1.0 1.0 0.1 0.3 0.3 0.3 0.3 0.0 0.4 0.7 0.4 0.5 0.2
d14:2/26:1 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0
d16:0/20:0 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.1 0.0
d16:1/18:0 0.2 0.2 0.2 0.2 0.0 0.2 0.1 0.2 0.2 0.1 0.0 0.0 0.0 0.0 0.0 0.2 0.3 0.3 0.2 0.0
d16:1/20:0 3.3 2.4 2.4 2.7 0.5 2.2 1.4 2.1 1.9 0.4 1.2 1.3 1.1 1.2 0.1 3.1 2.8 2.8 2.9 0.1
d16:1/22:0 4.0 3.4 3.1 3.5 0.5 3.0 2.3 3.0 2.8 0.4 1.6 1.8 1.6 1.6 0.1 2.4 3.0 2.9 2.8 0.3
d16:1/22:1 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0
d16:1/24:0 0.9 0.7 0.7 0.8 0.1 0.7 0.5 0.5 0.6 0.1 0.4 0.3 0.3 0.3 0.0 0.4 0.6 0.5 0.5 0.1
d16:2/14:0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.2 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.2 0.2 0.3 0.2 0.1
d16:2/18:0 0.3 0.2 0.2 0.2 0.0 0.5 0.3 0.4 0.4 0.1 0.1 0.1 0.1 0.1 0.0 0.3 0.4 0.5 0.4 0.1
d16:2/20:0 1.5 1.4 1.3 1.4 0.1 5.0 4.3 5.2 4.8 0.5 1.0 1.1 1.0 1.0 0.1 5.0 6.0 6.3 5.8 0.7
d16:2/20:1 0.0 0.1 0.1 0.1 0.0 0.1 0.0 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.0
d16:2/22:0 1.9 1.7 1.6 1.7 0.1 5.6 5.6 7.0 6.1 0.8 1.3 1.4 1.3 1.3 0.1 5.6 7.3 6.2 6.4 0.9
d16:2/24:0 0.2 0.2 0.2 0.2 0.0 0.6 0.6 0.7 0.6 0.1 0.1 0.2 0.2 0.2 0.0 0.6 0.6 0.6 0.6 0.0
d16:2/24:1 0.0 0.0 0.0 0.0 0.0 0.4 0.3 0.4 0.4 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.3 0.1 0.2 0.1
d18:0/18:0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0
d18:1/16:1 0.1 0.1 0.0 0.0 0.0 0.1 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
d18:1/18:0 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.2 0.1 0.1 0.1 0.0
d18:1/18:1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.1 0.0
d18:1/20:0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.1 0.1 0.1 0.1
d18:1/22:0 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.0 0.0 0.0 0.1 0.1 0.1 0.1 0.0
d18:2/16:0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
d14:1/18:1(OH) 0.1 0.1 0.1 0.1 0.0 0.1 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.0
d14:1/20:0(OH) 0.4 0.3 0.3 0.3 0.1 0.4 0.2 0.2 0.3 0.1 0.2 0.1 0.1 0.1 0.0 0.2 0.2 0.3 0.2 0.0
d14:1/20:1(OH) 0.7 0.7 0.5 0.6 0.1 0.5 0.6 0.8 0.6 0.2 0.3 0.3 0.2 0.3 0.1 0.3 0.4 0.5 0.4 0.1
d14:1/22:0(OH) 1.3 1.3 1.0 1.2 0.1 1.6 1.0 1.1 1.2 0.3 0.5 0.4 0.4 0.4 0.0 1.0 1.0 1.1 1.0 0.0
d14:1/22:1(OH) 1.2 1.4 0.9 1.2 0.3 0.9 0.9 1.6 1.2 0.4 0.4 0.5 0.4 0.4 0.1 0.5 0.8 0.8 0.7 0.1
d14:1/24:0(OH) 5.4 4.6 4.4 4.8 0.6 3.9 3.1 3.3 3.4 0.4 1.9 2.0 1.8 1.9 0.1 2.1 2.2 2.1 2.1 0.0
d14:2/18:0(OH) 0.3 0.2 0.2 0.2 0.0 0.2 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.2 0.2 0.2 0.1
d14:2/18:1(OH) 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0
d14:2/20:0(OH) 1.2 0.9 0.9 1.0 0.2 2.3 1.3 1.5 1.7 0.5 0.9 0.8 0.7 0.8 0.1 1.4 2.8 1.8 2.0 0.7
d14:2/20:1(OH) 0.2 0.1 0.1 0.1 0.0 0.4 0.3 0.4 0.4 0.1 0.1 0.1 0.1 0.1 0.0 0.2 0.2 0.2 0.2 0.0
d14:2/22:0(OH) 2.5 1.9 2.0 2.1 0.3 4.3 2.8 3.3 3.5 0.8 2.5 2.6 2.4 2.5 0.1 3.2 4.5 3.6 3.8 0.7
d14:2/22:1(OH) 0.2 0.3 0.2 0.2 0.1 0.3 0.2 0.4 0.3 0.1 0.1 0.2 0.1 0.1 0.0 0.2 0.3 0.2 0.2 0.0
d14:2/24:0(OH) 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.0 0.1 0.2 0.2 0.2 0.0 0.1 0.2 0.1 0.1 0.0
d16:1/18:1(OH) 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0
d16:1/22:0(OH) 0.4 0.4 0.4 0.4 0.0 0.6 0.3 0.3 0.4 0.2 0.2 0.2 0.1 0.2 0.0 0.4 0.3 0.3 0.3 0.1
d16:1/24:0(OH) 0.3 0.2 0.3 0.3 0.0 0.3 0.3 0.2 0.3 0.0 0.1 0.2 0.1 0.1 0.0 0.2 0.2 0.2 0.2 0.0
d16:2/18:0(OH) 0.1 0.1 0.1 0.1 0.0 0.1 0.0 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.0
d16:2/20:0(OH) 1.1 1.5 1.2 1.3 0.2 1.9 0.8 1.0 1.2 0.6 0.9 1.2 0.8 1.0 0.2 1.4 2.1 1.2 1.5 0.5
d16:2/22:0(OH) 1.6 4.0 2.7 2.8 1.2 1.4 1.1 1.2 1.2 0.2 2.1 2.6 2.1 2.3 0.3 1.8 2.3 1.5 1.8 0.4










































































































































































































































































































































































































































































































































































































































































































































































































































































































f. Sphingolipids wt (female) vs. sply (female) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
d14 Cer 
d16 Cer 
d18 Cer 
OH-Cer 
d14 GluCer 
d16 GluCer 
OH-GluCer 
d14 PECer 
d16 PECer 
d18 PECer 
OH-PECer 
